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1. ABBREVIATIONS 
12/15-LO 1β/15-lipoxygenase  
15-S-HETE 15-(S)-Hydroxyeicosatetraeonic acid 
ADP Adenosine di-phosphate 
AGEs Advanced glycation end products  
ALDH Aldehyde dehydrogenase 
AMP Adenosine monophosphate 
AMPK Adenosine monophosphate-activated protein kinase  
ATF4 Activating-transcription factor 4  
ATF6 Activating-transcription factor 6 
ATP Adenosine triphosphate 
BiP Binding immunoglobulin protein 
CAMKII Calcium activates Caβ+/calmodulin-dependent protein kinase II 
CHOP C/EBP homologous protein  
ECM Extra-cellular matrix 
eIF2α Eukaryotic translation initiation factor βα  
ER Endoplasmic reticulum 
ERAD ER-associated degradation pathway 
ERK Extracellular signal regulated kinase  
ETC Electron transport chain 
FAD Flavin adenine dinucleotide  
FCCP Carbonyl cyanide-4-phenylhydrazone 
GADD34 Growth arrest and DNA damage γ4 
GFAD Glutamine-fructose-6-phosphate amidotransferase 
GLUT Glucose transporter 
GRP78 78 kDa glucose-regulated protein 
H2O2 Hydrogen peroxide  
HBSS Hank’s balanced salt solution  
HFpEF Heart failure with preserved ejection fraction  
HG High glucose 
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HLA Human leukocyte antigen 
HM High mannitol 
HNE Hydroxynonenal 
IMM Inner mitochondrial membrane 
I/R Ischemia/reperfusion  
IL-1β Interleukin-1ȕ 
IR Insulin receptor 
IRE-1 Inositol-requiring kinase-1  
IRS Insulin receptor substrates 
KO Knockout 
LV Left ventricle 
MAMs Mitochondria associated membranes  
MAO Monomaine oxidase 
MEM Minimum essential media  
Mn-SOD Manganese-superoxide dismutase 
MPTP Mitochondrial permeability transition pore 
MRI Magnetic resonance imaging 
mTOR Mammalian target of rapamycin 
MTR MitoTracker Red CM-HβXROS  
NADPH Nicotinamide adenine dinucleotide phosphate 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells  
NG Normal glucose 
NLRP3 Nucleotide-binding oligomerization domain-like receptors with pyrin 
domain 
NOS Nitric oxide synthase 
Nox NADPH oxidase 
Nrf2 Nuclear factor (erythroid-derived β)-like-β factor  
NRVMs Neonatal rat ventricular myocytes  
OGT O-GlcNAc transferase 
OMM Outer mitochondrial membrane 
PERK Protein kinase R-like ER kinase  
PI3K Phosphoinositide γ-kinase 
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PIP2 Phosphatidylinositol 4,5-bisphosphate  
PIP3 Phosphatidylinositol γ,4,5-trisphosphate 
PKB Protein kinase B 
PV Pressure volume 
RAGE Receptor for advance glycation end products 
ROS Reactive oxygen species 
S1P Sphingosine-1-phosphate  
SERCA Sarco/ER Caβ+ ATPase 
SGLT Sodium/glucose cotransporter family 
SIRT1 Sirtuin 1 
STZ Streptozotocin 
T1D Type 1 diabetes 
T2D Type β diabetes 
TAC Transverse aortic constriction 
TGF-β Transforming growth factor-ȕ 
TMRM Tetramethylrhodamine 
TNFα Tumor necrosis factor α  
TUDCA Tauroursodeoxycholic acid  
UPR  Unfolded protein response 
WT Wild type 
XBP1 X-box-binding protein 1 
XO Xanthine oxidase 
ΔΨm Mitochondrial membrane potential 
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2. SOMMARIO 
Le malattie cardiovascolari sono le principali cause di morte tra i pazienti diabetici. Tra 
i vari meccanismi che contribuiscono allo sviluppo della cardiomiopatia diabetica, lo stress 
ossidativo ha ricevuto un’attenzione clinica e sperimentale significativa. Tuttavia, l’uso di 
terapie antiossidanti in studi clinici su larga scala è risultato inefficace nel trattamento di 
questi disturbi patologici. Nel complesso, questi studi indicano una reale necessità di 
sviluppare strategie terapeutiche volte a inibire specifiche fonti di specie reattive dell'ossigeno 
(ROS). Lo scopo di questa tesi è stato quello di valutare il ruolo delle monoammino ossidasi 
(MAO), enzimi mitocondriali localizzati nella membrana esterna, nello stress ossidativo e 
nella disfunzione mitocondriale in cardiomiociti esposti ad elevate concentrazione di glucosio 
(in vitro) ed il loro contributo in vivo nei danni cardiaci in un modello di T1D. 
Inizialmente, abbiamo valutato la formazione di ROS e la funzione mitocondriale in 
cardiomiociti primari trattati con alti livelli di glucosio (HG) e/o interleuchina-1ȕ (IL-1ȕ), una 
citochina pro-infiammatoria presente in livelli elevati in pazienti diabetici. Le cellule esposte 
a questi stimoli mostrano un aumento della formazione di ROS, accompagnata da disfunzione 
mitocondriale, come determinato dal minore potenziale di membrana mitocondriale. La 
pargilina, un inibitore MAO, previene completamente queste alterazioni, suggerendo che HG 
e IL-1ȕ inducano la formazione di ROS e le disfunzione mitocondriale MAO-dipendente. 
 Inoltre, per valutare se l’attività della MAO sia coinvolta nell’interazione tra i mitocondri ed 
il reticolo endoplasmatico (ER) e se possa determinare l’attivazione del’Unfolded Protein 
Response (UPR), in questo modello abbiamo misurato marcatori di stress dell’ER. È 
interessante notare come, in cardiomiociti adulti, l'espressione della proteina transcription 
factor 4 (ATF4), della growth arrest and DNA damage-inducible protein (GADDγ4), 78 kDa 
glucose-regulated protein (GRP78) e i livelli di fosforillazione di IRE1α (inositol-requiring 
enzyme 1α) siano significativamente elevati, il che dimostra la chiara presenza di stress del 
reticolo (ER). La somministrazione di pargilina previene e blocca queste alterazioni, 
suggerendo che MAO sia coinvolto nel processo di UPR indotto dalla combinazione di alto 
glucosio e IL-1ȕ. Inoltre questi dati suggeriscono che, almeno in queste condizioni, la 
formazione di ROS MAO-dipendente è a monte dello stress del reticolo (ER) e svolge un 
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ruolo importante nell’interazione tra mitocondri, infiammazione del reticolo in cardiomiociti 
esposti a condizioni simulanti il diabete.  
Dato il coinvolgimento della MAO nel danno cellulare causato da HG e IL-1ȕ, abbiamo 
valutato il suo ruolo nella disfunzione cardiaca in modelli murini di diabete di tipo 1 (T1D) 
indotta da trattamento con streptozotocina (STZ). La rigidità diastolica, un indice di 
disfunzione diastolica, era significativamente aumentata nei topi STZ, mentre la frazione di 
eiezione, un indice di funzione sistolica, è rimasta invariata. Inoltre, i marcatori di stress 
ossidativo (4-idrossinonenale) e UPR (ATF4 e GADDγ4) sono risultati significativamente 
aumentati nei cuori STZ rispetto al controllo. È importante sottolineare come i topi diabetici 
trattati con la pargilina, inibitore specifico per MAO, abbiano mostrato una funzione 
diastolica preservata e l’assenza di stress ossidativo e dell’ ER. In accordo con studi 
precedenti dove si dimostra come la fibrosi è una delle caratteristiche principali nella 
cardiomiopatia diabetica, i cuori dei topi diabetici evidenziano una maggiore deposizione di 
collagene. È interessante notare che la somministrazione di pargilina ha impedito questa 
alterazione, suggerendo che l'attività MAO rivesta un ruolo cruciale nella progressione della 
fibrosi in questi animali. Al fine di determinare se la fibrosi MAO-mediata sia dovuta al 
rilascio di fattori pro-infiammatori e pro-fibrotici da mastociti cardiaci, abbiamo valutato la 
loro degranulazione. Abbiamo osservato che, la degranulazione dei mastociti è aumentata di 
quasi β volte nei cuori diabetici rispetto ai topi di controllo. L’inibizione MAO ha 
completamente bloccato l'attivazione dei mastociti nei topi diabetici. Questi dati indicano un 
ruolo completamente nuovo di questi flavoenzimi nell'attivare mastociti cardiaci alla base del 
rimodellamento della matrice extracellulare, nella fibrosi e in ultima analisi, nella disfunzione 
del ventricolo sinistro (LV) in T1D. 
Complessivamente, questi risultati dimostrano non solo come le MAO contribuisca alla 
formazione di ROS e alla disfunzione mitocondriale indotta da HG e dall’infiammazione, ma 
anche che queste specie reattive perturbano la funzione dell’ER e portano all’attivazione 
dell’UPR. Inoltre, abbiamo dimostrato come questi flavoenzimi svolgano un ruolo importante 
nella formazione di un circolo vizioso tra stress ossidativo e infiammazione, che è 
probabilmente la causa della fibrosi cardiaca e della disfunzione diastolica ventricolare 
sinistra nei topi diabetici. Gli inibitori MAO sono clinicamente disponibili e vengono 
utilizzati per il trattamento di diverse malattie neurologiche e neurodegenerative. I risultati del 
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nostro studio suggeriscono come l'inibizione MAO potrebbe essere una strategia terapeutica 
promettente anche per il trattamento delle complicazioni cardiovascolari nel diabete. 
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3. SUMMARY 
Cardiovascular disease is the leading cause of death among diabetic patients. Amongst 
various mechanisms proposed to contribute to the development of diabetic cardiomyopathy, 
oxidative stress has received significant experimental and clinical evaluation. However, large 
scale clinical trials using antioxidant therapies for the treatment of these pathological 
disorders have been ineffective. Collectively, these studies point towards a serious need to 
develop therapeutic strategies aimed at inhibiting specific sources of reactive oxygen species 
(ROS). In the present thesis, we investigated the role of monoamine oxidases (MAOs), outer 
mitochondrial enzymes that generate HβOβ, in oxidative stress and mitochondrial dysfunction 
in cardiomyocytes exposed to diabetic milieu and cardiac damage in type 1 diabetes (T1D) 
mice in vivo. 
Initially, we assessed ROS formation and mitochondrial function in primary 
cardiomyocytes treated with high glucose (HG) and/or interleukin-1ȕ (IL-1ȕ), a pro-
inflammatory cytokine found to be elevated in diabetic patients. Cells exposed to these 
stimuli displayed an increase in ROS formation which was accompanied by mitochondrial 
dysfunction as documented by decreased mitochondrial membrane potential. MAO inhibitor 
pargyline completely prevented these alterations, suggesting that HG and IL-1ȕ induce ROS 
formation and mitochondrial dysfunction in a MAO-dependent manner. Moreover, to study 
whether MAO activity is also involved in endoplasmic reticulum (ER)-mitochondria cross-
talk and activation of unfolded protein response (UPR), we assessed markers of ER stress in 
this model. Interestingly, in adult cardiomyocytes, protein expression of activating 
transcription factor 4 (ATF4), growth arrest and DNA damage-inducible protein (GADDγ4), 
78 kDa glucose-regulated protein (GRP78) and phosphorylation levels of IRE1α (inositol-
requiring enzyme 1α) were significantly upregulated, marking the clear occurrence of ER 
stress. Pargyline administration abrogated these changes, suggesting that MAO is involved in 
HG and IL-1ȕ induced UPR. Moreover, this suggests that, at least in this setting, MAO-
dependent ROS formation is upstream of ER stress, and play an important role in the cross-
talk between mitochondria, inflammation and ER stress occurring in cardiomyocytes exposed 
to diabetic milieu.  
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Given the involvement of MAO in HG and IL-1ȕ induced cell damage, we investigated 
its role in cardiac dysfunction in streptozotocin (STZ)-induced T1D. We found that diastolic 
stiffness, an index of diastolic dysfunction, was significantly increased in STZ mice, whereas 
ejection fraction, an index of systolic function, remained unchanged. Moreover, markers of 
oxidative stress (4-hydroxynonenal) and UPR (ATF4 and GADDγ4) were significantly 
increased in STZ hearts as compared to controls. Importantly, STZ mice treated with MAO 
inhibitor pargyline displayed preserved diastolic function and absence of ER and oxidative 
stress. In agreement with previous reports showing that fibrosis is one of the major features of 
diabetic cardiomyopathy, we found that hearts from STZ-treated mice displayed increased 
collagen deposition. Interestingly, pargyline administration prevented this alteration, 
suggesting that MAO activity plays a crucial role in the progression of fibrosis in these 
animals. To understand whether MAO-mediated fibrosis was due to release of pro-
inflammatory and pro-fibrotic factors from cardiac mast cells, we assessed mast cell 
degranulation. Indeed, mast cell degranulation increased by almost β-fold in STZ hearts as 
compared to control mice. MAO inhibition completely blocked the activation of mast cells in 
diabetic mice. These data indicate the novel role of these flavoenzymes in activating cardiac 
mast cell thereby leading to the remodeling of the extracellular matrix, fibrosis and 
ultimately, left ventricle (LV) dysfunction in T1D. 
Collectively, these results demonstrate that MAOs not only contribute to HG and 
inflammation induced mitochondrial ROS formation and dysfunction, but they also perturb 
ER function leading to the activation of UPR. Moreover, we showed that these flavoenzymes 
play a major role in the formation of a vicious cycle between oxidative stress and 
inflammation, which is likely the underlying cause of cardiac fibrosis and LV diastolic 
dysfunction in T1D mice. MAO inhibitors are clinically available and are being used for the 
treatment of several neurological and neurodegenerative diseases. Results from our study 
suggest that MAO inhibition could be a promising therapeutic strategy also for the treatment 
of cardiovascular complications in diabetes.  
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4. INTRODUCTION 
4.1 DIABETES 
Diabetes is a chronic condition associated with high levels of glucose in the blood. 
Pancreatic ȕ-cells release peptide hormone insulin in the blood stream to maintain the levels 
of glucose in the blood. This hormone triggers the uptake of glucose, fatty acids and amino 
acids into liver, adipose tissue and muscle and promotes the storage of these nutrients in the 
form of glycogen, lipids and proteins, respectively [1]. In diabetic or pre-diabetic conditions, 
either the pancreatic islets do not secrete insulin or the body cells become insulin resistant, 
leading to high blood sugar.  
The common symptoms of diabetes include  
 Hunger and fatigue 
 Frequent urination (polyuria) 
 Extreme hunger even after eating adequate amounts of food (type 1) 
 Slow healing 
 Weight loss (type 1), obesity (type β) 
 Blurry vision 
 Tingling in the hands and/or feet 
 Sometimes dry mouth, itchy skin 
The number of people affected by diabetes is rapidly increasing. As shown in Figure 1, 
according to IDF (International Diabetes Federation) one in eleven adults has diabetes and 
this ratio is expected to further increase in coming years. These statistics clearly indicate a 
need for the better understanding of the pathophysiology of this disease.  
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Figure 1. Global prevalence of diabetes. The figure shows the distribution of diabetic people in 
different geographical locations in the year β015 and expected numbers for the year β040. Source: 
International Diabetes Federation. IDF Diabetes Atlas, 7th edition, β015. 
http://ww.idf.org/diabetesatlas 
The two main types of diabetes are type 1 diabetes (T1D) and type β diabetes (TβD). A 
third type, gestational diabetes, develops only during pregnancy and is less common. 
T1D, previously known as ‘Insulin-dependent diabetes mellitus’, is a condition in 
which destruction of pancreatic ȕ-cells leads to insulin deficiency. It accounts for 5-10 
percent of all the cases of diabetes and it is known as an autoimmune disorder [β]. A recent 
study reviewed several environmental risk factors including intestinal microbiota, dietary 
factors and viral infections that might contribute to the development and progression of T1D 
[γ]. Besides environmental factors, the risk of developing T1D is increased by certain variants 
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of the HLA-DQA1, HLA-DQB1, and HLA-DRB1 genes [4]. These genes belong to the family 
of human leukocyte antigen (HLA) complex. HLA complex genes encode for glycoproteins 
that are found on cell surface and help immune system to distinguish body's own proteins 
from proteins made by foreign invaders such as viruses and bacteria. In T1D, the immune 
system loses the ability to distinguish between these proteins and thus, destroys body’s own 
pancreatic ȕ-cells. So far, daily insulin injection and islet transplantation have been 
demonstrated to effectively maintain glucose homeostasis in T1D patients [5, 6]. However, 
islet transplantation is very limited due to the scarcity of donated islets. In this regard, several 
groups have made progress towards the production of ȕ-cells in vitro from pluripotent stem 
cells or somatic cell types including α cells, pancreatic exocrine cells, gastrointestinal stem 
cells, fibroblasts and hepatocytes [5, 7, 8].  
TβD is a metabolic disorder characterized by hyperglycemia, insulin resistance, and 
relative insulin deficiency [9]. Genes and environment together are important determinants of 
insulin resistance and ȕ-cell dysfunction in TβD. Several gene loci including PPARG have 
been associated with obesity, insulin resistance and ȕ-cell function [10]. Apart from increased 
caloric intake and decreased energy expenditure, other factors, such as dietary fat 
(particularly saturated fat), ageing, ethnicity and microbiome, seem to be important in TβD 
development [10, 11]. Several oral and injectable drugs, such as metformin, miglitol, 
alogliptin and pramlintide, are used for the treatment of TβD [10, 1β], but these treatments are 
not able to maintain ȕ-cell function. Therefore, new therapeutic targets, including AMP-
activated protein kinase (AMPK), sirtuin 1 (SIRT1), fibroblast growth factor β1, forkhead 
box protein O1 and interleukin-1ȕ (IL-1ȕ) receptor antagonist have been proposed for the 
treatment of TβD [10].  
4.1.1 Glucose uptake  
Glucose is an important fuel for all the tissues in the body and normal glucose 
metabolism is vital for health. Glucose transport is mediated by two families of glucose 
transporters, facilitative glucose transporter family (GLUT) and Na+/glucose cotransporter 
family (SGLT) [1γ]. SGLT transports glucose into the cell using the electrochemical gradient 
of Na+ [1γ]. GLUT and SGLT families consist of thirteen members (GLUT1-1β and H+-myo-
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inositol transporter) and six members (SGLT1-6), respectively [14]. Expression of different 
isoforms of both the GLUT and SGLT families has been shown to be cell type specific [14]. 
Among all the reported glucose transporters, GLUT1-4 have been extensively studied. 
GLUT1 is known as the most ubiquitously distributed isoform in a variety of human tissues; 
in particular, it is shown to be expressed in endothelial and epithelial-like barriers of the 
brain, eye, peripheral nerve, placenta and lactating mammary gland [15]. Besides glucose, 
other substrates of GLUT1 include galactose, mannose and glucosamine [15]. GLUTβ has a 
low affinity for glucose and a high affinity for glucosamine and its expression mainly occurs 
in the kidney and intestinal absorptive epithelial cells where it is located in the basolateral 
membrane [14]. Besides kidney, GLUTβ is also expressed in liver, pancreas and brain. In 
hepatocytes it is involved in the release of gluconeogenesis-synthesized glucose into the 
blood. GLUTγ transports galactose, mannose, maltose, xylose and dehydroascorbic acid in 
addition to glucose [14]. Although GLUTγ mRNA is present in several human tissues, 
GLUTγ protein is mainly detected in the brain and it is therefore considered as neuro-specific 
glucose transporter [15]. GLUT4 is the insulin-sensitive transporter of this family and its role 
has been extensively studied in diabetes. Its expression is highest in insulin-sensitive tissues 
including brown and white adipose tissue, skeletal and cardiac muscle [15]. It has a similar 
affinity for glucose as GLUT1 (Km of 5-6 mM), and can also transport glucosamine and 
ascorbic acid [14, 15].  
4.1.1.1 Glucose transporter type 4 translocation and insulin signaling 
Inside the cell GLUT4 continuously undergoes a process known as regulated recycling, 
in which endocytosis, sorting into specialized vesicles, exocytosis, tethering, docking and 
fusion of the protein are tightly regulated [16]. In the absence of insulin, most of the GLUT4 
is stored in the cytoplasmic vesicles within the cell [16]. Both insulin and exercise acutely 
stimulate GLUT4 recruitment to the cell surface of muscle and adipose cells, but the signaling 
mechanisms initiated by these two physiological stimuli are different. Insulin stimulates the 
translocation of GLUT4 to the plasma membrane via targeted exocytosis and at the same time 
attenuates the endocytosis process [17]. Thus, the amount of glucose that is transported into 
adipose and muscle cells depends upon GLUT4 density on the plasma membrane and the 
amount of time that the transporter is maintained at that site.  
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Insulin activates the insulin receptor (IR) tyrosine kinase which phosphorylates and 
recruits different substrates, such as proteins from family of insulin receptor substrates (IRS) 
(Figure β) [18]. Phosphorylated IRS display binding sites for numerous signaling partners, 
among which the recruitment of phosphoinositide γ-kinase (PIγK) has a major role in insulin 
signaling. PIγK catalyzes the phosphorylation of phosphatidylinositol 4,5-bisphosphate 
(PIPβ) to phosphatidylinositol γ,4,5-trisphosphate (PIPγ) [19]. PIPγ is dephosphorylated and 
converted back to PIPβ by phosphatase and tensin homolog (PTEN) [19]. Dysfunction of 
either PIγK or PTEN has been linked to various diseases including cancer and diabetes [19]. 
PIPγ triggers the activation of the protein kinase B (PKB), also known as Akt, through the 
actions of two intermediate protein kinases, PDK 1 (pyruvate dehydrogenase lipoamide 
kinase isozyme 1) and rapamycin-insensitive companion of mammalian target of rapamycin 
(Rictor/mTOR) [18]. Aktβ isoform appears to control GLUT4 trafficking in adipose and 
muscle cells and glucose output regulated by insulin signaling in liver [15]. Although several 
Aktβ substrates responsible for insulin-dependent effects on GLUT4 trafficking machinery 
have been identified, only a few have been extensively studied. These include the GTPase 
activating protein AS160, which contains multiple Aktβ phosphorylation sites and catalyzes 
the inactivation of Rab proteins βA, 8A, 10 and 14 in vitro [15, 16]. Rab proteins are known 
to be critical organizers of intracellular membrane trafficking. However, AS160 knockdown 
partially inhibits insulin-dependent translocation of GLUT4 suggesting that unknown Aktβ 
substrate proteins must contribute to overall GLUT4 regulation by insulin [15, 16]. 
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Figure 2. Insulin- and muscle contraction-mediated GLUT4 translocation. Insulin signaling 
through PIγK and muscle contraction through activation of AMPK mediate GLUT4 translocation to 
the cellular plasma membrane. AMPK activity is regulated by both increased AMP/ATP ratio and 
elevated intracellular calcium concentrations. Both PIγK and AMPK pathways result in the 
phosphorylation Aktβ substrate AS160 that mediates GLUT4 translocation. GLUT4: glucose 
transporter type 4, PIγK: phosphoinositide γ-kinase, AMPK: adenosine monophosphate-activated 
protein kinase, ATP: adenosine tri-phosphate. From Mackenzie et al., β014 [β0].  
In addition to insulin-mediated pathway, AS160 phosphorylation can be induced by 
muscle contraction through a PIγK independent mechanism (Figure β). Contraction-induced 
AS160 phosphorylation is mediated by adenosine monophosphate-activated protein kinase 
(AMPK), providing a potential intersection for insulin and exercise-mediated signaling to 
GLUT4 [16]. Muscle contraction results in a transient increase in Caβ+ levels along with an 
increase in AMP/adenosine tri-phosphate (ATP) ratio leading to AMPK activation. Calcium 
activates Caβ+/calmodulin-dependent protein kinase II (CAMKII), which then contributes to 
AMPK activation through upstream kinases CaMKKα and ȕ, at least in cultured cell lines and 
ex vivo brain slices [15, 16, β1]. Muscle glycogen appears to be a negative regulator of 
AMPK activity [β1]. It has been demonstrated that in rat skeletal muscle glycogen suppresses 
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AMPK signaling, thus providing a negative feedback mechanism for AMPK-mediated 
glucose uptake [ββ]. However, downstream targets of this protein kinase involved in GLUT4 
translocation are not yet known. Nevertheless, it has been demonstrated that simultaneous 
inhibition of AMPK and Akt activity is not able to completely prevent GLUT4 translocation 
to plasma membrane, suggesting that additional signals are involved in insulin-induced 
glucose uptake. 
Besides insulin and muscle contraction, several other stress signals are also known to 
enhance glucose uptake in skeletal muscle. For instance, hypoxia, inhibitors of glycolysis and 
electron transport, and uncoupling of oxidative phosphorylation increase glucose uptake at 
least partially through AMPK and modulation of the AMP/ATP ratio (Figure β) [16, βγ].  
4.1.2 Complications associated with diabetes 
Chronic hyperglycemia is a life threatening risk factor that results in organ and tissue 
damage in the long term. One of the acute metabolic complications associated with mortality 
includes diabetic ketoacidosis occurring mainly in T1D [βγ]. The long-term vascular 
complications associated with diabetes are divided into two groups, (i) microvascular disease, 
resulting from the damage of small blood vessels and (ii) macrovascular disease, resulting 
from the damage of the arteries. Hyperglycemia-associated vascular complications are the 
major source of morbidity and mortality in both T1D and TβD. Thus, it is important for 
researchers and physicians to understand the relationship between diabetes and vascular 
disease because the prevalence of diabetes continues to increase all over the world. 
Microvascular complications include retinopathy, nephropathy and neuropathy. The major 
macrovascular complications include coronary artery disease, peripheral arterial disease, and 
stroke. Moreover, there is also myocardial dysfunction that is one of the deadliest 
complications associated with diabetes [βγ]. Other chronic complications of diabetes include 
depression, dementia and sexual dysfunction. 
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4.2 DIABETIC CARDIOMYOPATHY 
Diabetic cardiomyopathy is a result of diabetes-induced changes in the structure and 
function of the heart and it is diagnosed only if there is cardiac dysfunction in the absence of 
coronary artery disease [β4]. Cardiovascular disease is the leading cause of mortality and 
morbidity in diabetic patients [β4]. Thus, a better understanding of its pathophysiology is 
necessary for early diagnosis and the development of treatment strategies.  
Previous studies using magnetic resonance imaging (MRI) demonstrated that 
hyperglycemia and insulin resistance are associated with an increase in left ventricle (LV) 
mass and LV-mass to LV end-diastolic volume ratio [β5, β6]. It has been frequently observed 
that, in diabetic patients, diastolic dysfunction occurs at early stages and precedes systolic 
dysfunction [β5, β7, β8]. LV diastolic dysfunction is detected in almost 6γ% of the diabetic 
patients [β9]. Diastole is the part of cardiac cycle that occurs when the ventricles are relaxing 
and filling with blood. During diastole, the pressure in the ventricles drops and mitral valve 
opens causing the accumulated blood from left atrium to flow into the ventricle [β8]. 
Impairment in this process, such as increase in ventricle stiffness and decrease in ventricle 
relaxation, leads to diastolic dysfunction [γ0, γ1]. Thus, the inability of the ventricle to accept 
an adequate amount of blood at normal diastolic pressure leads to diastolic heart failure. 
When this occurs in the absence of systolic dysfunction (Figure γ), it is commonly referred to 
as heart failure with preserved ejection fraction (HFpEF) [γβ].  
Diastolic heart failure can also be accompanied by systolic heart failure (Figure γ). 
Systole is a period of cardiac cycle when the ventricles contract. During systole, pressure in 
the ventricles increases and when it exceeds the pressure in the atria, tricuspid and mitral 
vales close [γγ]. The pressure in the ventricles keeps increasing and reaches its maximum 
until the pulmonary and aortic valves open in the ejection phase [γ4]. In this phase, blood 
flows through pulmonary artery and aorta from right and left ventricles, respectively. Thus, 
ejection fraction is the measurement of the pumping efficiency of the heart, i.e. the fraction of 
blood that is ejected by the ventricles with each cardiac cycle [γ5]. Normal ejection fraction 
ranges from 50 to 70%, while values below 40% indicate presence of systolic heart failure. 
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Figure 3. PV loop showing diastolic and systolic function. The figure shows PV loops for diastolic 
heart failure (A), systolic heart failure (B) and combination of diastolic and systolic heart failure (C) 
as compared to normal. PV: pressure-volume. From Zile et al., β00β [γ6] 
At an early stage, diabetic cardiomyopathy manifests as diastolic dysfunction with 
preserved ejection fraction [γ7]. In some patients, diastolic dysfunction may progress to 
compromised systolic function resulting in heart failure with reduced ejection fraction [γ7]. 
The mortality rate is 15-β0% in diabetic patients with systolic dysfunction [γ8]. Although the 
exact mechanism of diabetes associated LV dysfunction is not known, it appears that 
hyperglycemia initiates a series of adaptive and maladaptive processes contributing to the 
development of heart failure. 
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4.2.1 Hyperglycemia-induced pathways associated with vascular complications 
in diabetes 
Diabetic cardiomyopathy is a multi-factorial disease. Several mechanisms, including 
oxidative stress, inflammation, endoplasmic reticulum (ER) stress, metabolic derangements, 
abnormalities in ion homeostasis, alterations in structural proteins, apoptosis and fibrosis have 
been proposed to trigger diabetes-induced cardiac damage (Figure 4) [γ9]. Amongst these 
various mechanisms proposed, an increase in reactive oxygen species (ROS) formation has 
gained significant experimental and clinical evaluation [γ7, 40]. Hyperglycemia can increase 
ROS production by several pathways, including polyol pathway, formation of advanced 
glycation end products (AGEs), activation of protein kinase C (PKC), glucose auto-oxidation, 
and activation of the 1β/15-lipoxygenases (1β/15-LO) pathway [γ9]. 
 
Figure 4. Mechanisms involved in the development of diabetic cardiomyopathy. High glucose in 
T1DM and TβDM results in PKC activation, glucose auto-oxidation, AGE formation, abnormal 
calcium handling and ROS formation. Activation of these pathways leads to energy depletion, 
increased fibrosis, apoptosis, hypertrophy and impaired LV contractile function and relaxation. AGEs: 
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advanced glycation end-products, ASK1: apoptotic signal regulating kinase-1, FAO: fatty acid 
oxidation, GLUT-4: glucose transporter-4, GPCR: G protein coupled receptor, HBP: hexosamine 
biosynthesis pathway, IGF-1: insulin-like growth factor-1, LV: left ventricle, JNK: c-Jun N-terminal 
kinase, NADPH: nicotinamide adenine dinucleotide phosphate, NCX: sodium–calcium exchanger, O-
GlcNAc: O-linked ȕ-N-acetylglucosamine, PIγK: phosphoinositide-γ kinase, PKCȕ: protein kinase C-
ȕ, RTK: receptor tyrosine kinase, RyR: ryanodine receptor, SERCA: sarcoplasmic reticulum Caβ+ 
ATPase, T1DM: type 1 diabetes mellitus, TβDM: type β diabetes mellitus. From Huynh et al., β014 
[41] 
4.2.1.1 Polyol pathway 
Two major enzymes are involved in the polyol pathway, namely aldose reductase and 
sorbitol dehydrogenase (Figure 5). Under euglycemia, aldose reductase converts reactive 
aldehydes into alcohols, thus protecting the cell from toxic effects of aldehydes [4β]. 
Although the affinity of this enzyme for glucose is very low in normal conditions, in 
hyperglycemic conditions aldose reductase converts high amounts of glucose into sorbitol. In 
the next step, sorbitol is converted to fructose by sorbitol dehydrogenase with the production 
of NADH, potentially leading to increased ROS via NADH oxidase as shown in Figure 5 [4γ, 
44]. Furthermore, fructose-γ-phosphokinase can directly phosphorylate fructose resulting in 
the formation of a potent glycating agent, fructose-γ-phosphate. Fructose-γ-phosphate can 
subsequently result in the formation of γ-deoxyglucosone, a key intermediate known to 
accelerate the formation of AGEs [45]. 
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Figure 5. Role of aldose reductase in hyperglycemia-induced ROS formation. Under 
hyperglycemia, aldose reductase converts glucose into sorbitol at the expense of NADPH. In the next 
step, sorbitol is converted into fructose by sorbitol dehydrogenase resulting in the production of 
NADH, potentially leading to increased ROS via NADH oxidase. NADPH: nicotinamide adenine 
dinucleotide phosphate, ROS: reactive oxygen species. From Tang et al, β01β [44] 
A recent study demonstrated that inhibition of aldose reductase with tephrosia purpurea 
prevented the development of diabetic cataract in STZ-induced T1D rats [46]. Moroever, 
overexpression of human-aldose reductase leads to an increase in atherosclerosis in mice [47], 
suggesting a pathological role of this pathway in hyperglycemic conditions. Aldose reductase 
inhibitors have been used clinically for several years to prevent diabetic neuropathy; 
nevertheless, they have not been successful in preventing the occurrence of other diabetic 
complications. 
4.2.1.2 Formation of advanced glycation end products  
Glycation refers to the covalent bonding between proteins/lipids and sugars such as 
glucose. Glycation causes molecular rearrangements of proteins or lipids that lead to the 
generation of AGEs [48]. Several mechanisms through which AGEs are known to contribute 
to the pathogenesis of diabetic cardiomyopathy include formation of cross-links between key 
molecules in the extra-cellular matrix (ECM), permanently altering cellular structure and 
binding of AGEs to receptor for advance glycation end products (RAGE) [49]. In presence of 
high glucose, RAGE activation can directly induce NADPH oxidase (Nox) leading to 
increased ROS production [50]. Considering the detrimental effects of AGEs, several studies 
have tried to diminish their effects either by directly inhibiting AGEs or by preventing the 
interaction of AGEs with their receptors RAGE [51, 5β]. Clinical trials employing these 
inhibitors have been unsuccessful so far and further investigation is necessary in order to 
better understand the formation and function of these products. 
4.2.1.3 Activation of protein kinase C 
Glucose regulates intracellular levels of diacylglycerol, which is known to activate 
several PKC isoforms [4γ]. Besides diacylglycerol, polyol pathway, HβOβ and AGEs 
formation are also known to activate these kinases [5γ, 54]. PKC phosphorylates protein 
serine and threonine residues and is involved in receptor desensitization, modulation of 
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membrane structure events, transcription regulation, immune response and cell growth 
regulation [55]. Multiple studies have shown that PKCȕ-mediated p66Shc phosphorylation is 
required for its mitochondrial translocation, hydrogen peroxide (HβOβ) formation and cell 
death [56, 57]. Besides translocation of p66Shc, PKCȕ is also involved in the activation of 
Noxβ leading to an increase in ROS formation in cardiomyocytes exposed to high glucose 
[58]. These studies indicate towards the important role of PKC-mediated phosphorylation in 
pathophysiology of diabetic cardiomyopathy. 
4.2.1.4 Glucose auto-oxidation 
Hyperglycemia induces the activity of glutamine-fructose-6-phosphate 
amidotransferase (GFAD) in hexosamines synthesis pathway. GFAD activity has been 
associated with increased transcription of transforming growth factor-ȕ1 (TGF-ȕ1), a 
cytokine known to play a role the development of cardiac fibrosis in hyperglycemic 
conditions [59]. The exact mechanism of hexosamine pathway- or glucose auto-oxidation-
induced ROS production is not very well known. However, it is proposed that this pathway 
might be involved in the activation of PKC and thereby induce cellular changes as described 
above (Figure 4).  
4.2.1.5 Activation of the 12/15-Lipoxygenases pathway 
Activation of 1β/15 LO pathway is associated with ROS production in pathological 
conditions and hyperglycemia has been shown to increase the activity of these enzymes [60]. 
1β/15 LO inserts the molecular oxygen at 1β/15 carbon of polyunsaturated acids, such as 
arachidonic acid and linoleic acid, leading to the formation of oxidized lipids [61]. Studies 
have shown that LO and its products mediate growth factor effects in several cells types, 
including fibroblasts and mesangial cells [60, 61]. 15-(S)-hydroxyeicosatetraeonic acid (15-S-
HETE), a metabolized product of arachidonic acid, was found to be elevated in the urine of 
diabetic patients [6β]. It has also been shown that incubation of endothelial cells with 15-(S)-
HETE led to an increase in HβOβ production via xanthine oxidase (XO) in a dose dependent 
manner [6γ]. This study further illustrated that genetic ablation of 1β/15 LO gene completely 
blocks XO activity and prevents endothelial dysfunction in mice kept on high fat diet [6γ]. 
Even though LO inhibitor masoprocol improves insulin sensitivity in a rat model of type β 
diabetes [64], so far no clinical trials have been conducted.  
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4.3  ROS: A COMMON DENOMINATOR OF HYPERGLYCEMIA-INDUCED 
CHANGES 
Although several potential mechanisms underlying diabetic cardiomyopathy have been 
addressed in the past decade, oxidative stress is widely considered as one of the major causes 
for the pathogenesis of the disease [65-67]. Current consensus is that hyperglycemia- and 
hyperlipidemia-induced ROS formation is detrimental for cardiac function and leads to 
cardiac damage in both T1D and TβD [68]. Indeed, increased ROS production is well 
documented in multiple tissues in both animal and human diabetic subjects [γ9, 69]. Thus, it 
becomes important to understand the sources of ROS and their mechanism inside the cell.  
There are several sources of ROS in human tissue, including, Nox, XO, uncoupled 
nitric oxide synthase (NOS), arachidonic acid and mitochondria, but they vary in their 
pathological role and their importance depends on the disease and the organ.  
4.3.1 NADPH oxidase 
Nox is a family of membrane-bound enzyme complex composed of plasma membrane 
spanning cytochrome b558 (pββphox, gp91phox) and cytosolic components (rac, p47phox, 
p67phox, p40phox) as shown in Figure 6 [70]. It becomes activated following exposure to 
foreign microorganisms and promotes translocation of its cytosolic components to the plasma 
membrane to form an active NADPH complex that allows transfer of electrons to molecular 
oxygen to generate superoxide [70]. The reaction catalyzed by this enzyme is following: 
NADPH + βOβ → NADP + βOβ- + H+  
Nox specifically generate ROS as their primary function and have emerged as the major 
cellular ROS sources involved in several pathological conditions (Figure 6) [71]. Up to date, 
seven members of Nox family have been identified, namely Nox1–5, dual oxidase 1 (Duox 1) 
and Duox β [7β]. Among these, two Nox isoforms exist in the heart, Noxβ and Nox4. 
Although Noxβ is located in the cell membrane, Nox4 is localized in perinuclear ER and/or 
mitochondria [7γ, 74]. 
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Figure 6. Nox in the heart. Nox is a membrane-bound enzyme complex. It has two subunits: 
cytochrome b558, composed of gp91phox and pββphox, and multidomain regulatory subunits, 
composed of p40phox, p47phox and p67phox. When the enzyme is inactive, multidomain regulatory 
subunits exist in the cytosol as a complex whereas upon stimulation, p47phox undergoes 
phosphorylation, and the entire multidomain regulatory complex subsequently translocates to the 
membrane and associates with cytochrome b558 to form the active oxidase. The active complex uses 
NADPH as a substrate and transfers electron to oxygen leading to the production of superoxide. Nox: 
Nicotinamide adenine dinucleotide phosphate oxidases. From Kayama et al., β015 [7β] 
Several studies have reported the contribution of Nox to hyperglycemia-induced ROS 
production [75, 76]. It is well documented that the activity of Nox is increased in 
cardiomyocytes exposed to high glucose and in the heart of diabetic mice [75, 77]. Pathways 
reported to link glucose-induced ROS production via Nox include SGLT1, PKCȕ and 
calcium/calmodulin dependent kinase II (CaMKII) [58]. A recent study identified that 
glucose transport through SGLT1 is responsible for Noxβ activation and subsequent increased 
ROS production in cardiac myocytes exposed to high glucose [78]. This study further 
demonstrated that oxidative pentose phosphate pathway is required to provide Noxβ with the 
substrate NADPH and to produce ROS [78]. PKC is involved in high glucose-induced 
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activation of Noxβ through a positive feedback mechanism involving the RhoA/Rho kinase 
pathway [58]. Indeed, PKCȕ inhibition by LYγγγ5γ1 in cardiomyocytes treated with high 
glucose for 1β h prevented Noxβ dependent ROS production [58]. However, how PKCȕ is 
activated by high glucose levels was not addressed in these studies and thus warrants further 
investigation. Cellular influx of Caβ+ led to increased CaMKII phosphorylation along with 
upregulation of Nox components, p47phox and p67phox, and increased ROS formation in 
STZ model of T1D and neonatal cardiomyocytes exposed to high glucose [79]. Interestingly, 
CaMKII inhibitor attenuated these events indicating the involvement of this kinase in Nox-
induced ROS formation. However, although the role of Nox is confirmed in cardiovascular 
complications occurring in diabetes so far no clinical trials have been conducted with the 
inhibitors of these enzymes.  
4.3.2 Xanthine oxidase 
XO is a cytoplasmic enzyme that catalyzes the oxidation of hypoxanthine to xanthine 
and further converts xanthine to uric acid [80]. It uses Oβ as electron acceptor during this 
process and thus produces superoxide and HβOβ [80]. Hypoxanthine and XO have been shown 
to induce cell damage under ischemia-reperfusion conditions by reacting with Oβ and 
producing large amounts of superoxide and HβOβ. Moreover, inhibition of XO by allopurinol 
prevented cardiac damage in pacing-induced heart failure in dogs [81]. Rajesh et al. 
documented the role of XO in the development of fibrosis and oxidative stress in STZ-
induced T1D mice [8β]. Although XO inhibition has been proven beneficial in animal studies, 
it cannot be used to treat cardiovascular complications in patients, since human heart does not 
contain detectable amount of these enzymes [8γ, 84]. 
4.3.3 Mitochondrial sources of ROS 
Mitochondrial ROS formation and dysfunction have been implicated in the 
pathogenesis of diabetes and its complications [γ7, γ9, 58]. Indeed, cardiac mitochondria 
from diabetic patients were reported to be dysfunctional, displaying increased mitochondrial 
HβOβ emission, impaired mitochondrial respiratory capacity and increased levels of 
hydroxynonenal- (HNE) modified proteins [85]. It is proposed that a combination of several 
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mechanisms leads to mitochondrial dysfunction in diabetic hearts, including fatty acid-
induced mitochondrial uncoupling, increased ROS formation, mitochondrial proteome 
remodeling, impaired mitochondrial calcium handling and altered mitochondrial biogenesis. 
These changes might lead to compromised cardiac ATP generation and ultimately to cardiac 
dysfunction [γ7, γ9]. Altered mitochondrial function is depicted to oppose insulin signaling in 
two ways: first, by interfering with oxidation of fatty acyl-CoA and consequent accumulation 
of intracellular lipid and diacylglycerol, and second, through generation of ROS. Both 
processes lead to IRS-1 serine phosphorylation and interference with insulin signal 
transduction. Reduction in mitochondrial ROS formation either by overexpressing manganese 
superoxide dismutase (Mn-SOD) or by AICAR (5-aminoimidazole-4-carboxamide 
ribonucleoside), prevented mitochondrial damage and many hyperglycemia-induced events, 
both in vitro and in vivo [86, 87]. Electron transport chain (ETC), p66Shc and monoamine 
oxidase (MAO) are the major sources of ROS formation in mitochondria. 
4.3.3.1 Electron transport chain  
ETC is by far the major site of ATP production in mitochondria inside any given cell, 
and especially in cardiomyocytes (more than 90%). At the inner mitochondrial membrane 
(IMM), complexes of the ETC transfer electrons from NADH and FADHβ (Flavin adenine 
dinucleotide) to oxygen (Oβ), which is reduced to water (HβO). Transfer of electrons powers 
the movement of protons (H+) into the intermembrane space [88], generating an 
electrochemical proton gradient that drives the synthesis of ATP by the ATP synthase (Figure 
7) [88]. 
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Figure 7. Sites of superoxide production in the ETC. This scheme shows the proposed 
physiological (highlighted with light green/yellow boxes) and pathophysiological (highlighted with 
pink boxes) roles of superoxide generation by each respiratory electron transport complex and the 
proton motive force (Δp). Superoxide generation by complexes I, III, and flavoprotein of complex II 
mediates I/R injury and increases the pro-oxidant activity of aconitase, thus further augmenting I/R 
injury. PKA-mediated phosphorylation of complex IV under ischemic conditions predisposes complex 
IV to generate superoxide and augment I/R injury. ETC: electron transport chain, I/R: 
ischemia/reperfusion injury, PKA: protein kinase A. From Chen et al., β014 [89] 
A minor fraction of electron (about 0.1%) can leak from the ETC and cause the partial 
reduction of Oβ into superoxide. This process occurs at the level of first three complexes 
where flavins or quinones are able to act as single electron donors, especially under 
conditions that decrease the flow of electrons toward complex IV, where Oβ is fully reduced 
to HβO [90, 91]. Notably, ROS formation can also result from reverse electron flow. A recent 
study supported this concept by demonstrating that succinate accumulated during ischemia in 
vivo is oxidized during reperfusion, resulting in large ROS formation that is likely 
attributable to the reverse electron flow through complex I [9β]. Superoxide that does not 
cross IMM is rapidly dismutated into the freely permeable HβOβ by Mn-SOD [9γ]. It has been 
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shown that Mn-SOD deficient mice develop ROS toxicity and dilated cardiomyopathy [58]. 
Moreover, increased catalase expression or inhibition of ETC complexes I and II with 
rotenone and thenoyltrifluoroacetone, respectively, attenuate ROS formation in 
cardiomyocytes from animals with T1D and TβD [94, 95]. These studies underline the 
importance of ETC in this pathology and mitochondria as their source and target. 
Hyperglycemia-induced ROS formation is not observed in rho zero (ρ0) endothelial 
cells in which mitochondrial DNA is depleted and ETC is not functional [96]. A recent study 
demonstrated that hyperglycemia alters the function of respiratory chain in mitochondria via 
dysregulation of O-GlcNAcylation [97]. O-GlcNAc transferase (OGT) enzyme is located in 
the IMM and interacts with complex IV of the respiratory chain in normal conditions. In 
STZ-treated rats this enzyme is mislocalized to mitochondrial matrix and the interaction of 
OGT and complex IV is impaired leading to the loss of complex IV activity and reduced 
mitochondrial membrane potential [97]. Collectively, these studies show that mitochondria 
are important sites for ROS generation in hyperglycemic conditions and can further amplify 
this ROS formation by activating other sources of ROS inside the cell. 
Although ETC is considered as an important source of ROS formation, Nox and MAO 
are able to generate 10-fold higher levels of ROS in human atrial myocardium [98]. In 
addition to this, it is not possible to inhibit the respiratory chain in humans without 
jeopardizing a wide array of vital functions. Thus, inhibition of the ETC complexes cannot be 
considered as potential therapeutic strategy for the treatment of this multifactorial disease. 
4.3.3.2 p66Shc 
p66Shc is another important source of ROS in mitochondria. p66Shc is a ubiquitously 
expressed cytosolic adaptor protein [99, 100] and, along with p46Shc and p5βShc, is encoded by 
the ShcA gene. p46Shc and p5βShc are ubiquitous isoforms, derived from the same mRNA 
through alternative start sites [99, 101]. In contrast, p66Shc expression is restricted to certain 
cell types and stimulatory conditions through epigenetic modifications of its distinct 
promoter. Cells and mice lacking p66Shc show reduction in markers of oxidative stress [101]. 
Under stress conditions, this enzyme translocates to mitochondria and catalyzes the electron 
transfer from cytochrome c to oxygen, resulting in the formation of HβOβ [99, 100].  
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p66Shc is readily detected in neonatal cardiomyocytes, but it is barely detectable in the 
adult ventricle [99]. However, its expression is increased in a dog model of dilated 
cardiomyopathy [65]. Moreover, genetic ablation of p66Shc resulted in reduced hypertrophy 
and apoptosis induced by angiotensin II in vivo [99, 101]. Besides heart failure, p66Shc -
induced oxidative stress is also believed to exacerbate ischemia/reperfusion injury [100, 101]. 
Indeed, lack of this enzyme led to a significant decrease in oxidative stress in both ischemic 
muscles and isolated endothelial cells subjected to simulated ischemia [99].  
As described above, p66Shc can be phosphorylated at Ser-γ6 residue by PKCȕ, and this 
is required for its translocation to mitochondria. Importantly, hyperglycemia can directly 
activate PKC thus leading to increased ROS formation in diabetic conditions [10β]. 
Moreover, lack of p66Shc was shown to protect against diabetic cardiomyopathy by preventing 
the senescence of cardiac progenitor cells, a process that hampers cardiac and vascular cell 
turnover [10γ]. 
Genetic ablation of p66Shc has been proven protective in many pathologies, including 
cardiovascular complications. Unfortunately, there are no drugs available that can inhibit the 
ROS forming activity of p66Shc.  
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4.4 MONOAMINE OXIDASES 
4.4.1 Structural properties 
MAOs are flavoenzymes located at the outer mitochondrial membrane (OMM) and catalyze 
the oxidative deamination of catecholamines and biogenic amines resulting in the formation 
of HβOβ, aldehydes and ammonia [90]. These flavoenzymes exist in two isoforms, MAO-A 
and MAO-B (Figure 8) and are distinguished by different substrate specificity and their 
sensitivity to inhibitors. The sequence homology of the two isoforms is 70% and both the 
sequences contain the penta-peptide Ser-Gly-Gly-Cys-Tyr, in which the obligatory cofactor 
flavin adenine dinucleotide (FAD) is covalently bound to cysteine residue, namely Cys406 in 
MAO-A and Cysγ97 in MAO-B [90]. Human MAO-A (hMAO-A) is known to exist in 
monomeric form whereas rat MAO-A (rMAO-A) and human MAO-B (hMAO-B) exist as 
dimers [104]. hMAO-A contains a single hydrophobic cavity of ≈550 Å at its active site, 
which is smaller than hMAO-B (≈700 Åγ) but larger than that of rat MAO-A (≈450 Åγ) 
[104]. This study also proposed that the mutation Glu-151→Lys is responsible for hMAO-A 
transition from dimeric to monomeric form. Genes encoding for MAO-A and MAO-B are 
located side-by-side on the short arm of X-chromosome and have 9β% similarity in their 
sequence. In both the genes, exon 1β encodes for the covalent FAD binding site and is the 
most conserved exon, showing 94% amino acid identity between MAO-A and B [105].  
       
 
 
 
Figure 8. Ribbon structures of two isoforms of MAO. The covalent flavin moiety is shown in a ball 
and stick model in yellow. The flavin binding domain is in blue, the substrate domain in red and the 
membrane binding domain in green. MAO: monoamine oxidase; From Edmondson et al., β004 [105]. 
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4.4.2 Physiological roles 
MAO catalyzes the oxidative deamination of monoamines according to the following 
reaction: 
RCHβNR′R′′ + Oβ + HβO → RCHO + NR′R′′ + HβOβ 
This reaction is known to take place in two steps. In the first step, the cofactor FAD is 
reduced to yield an aldehyde intermediate and ammonia, while in the second step the oxidized 
form of the prosthetic group is restored with the concomitant production of HβOβ [90]:  
RCHβNHβ + MAO → RCHO + NHγ + MAO-reduced 
MAO-reduced +Oβ → MAO + HβOβ 
Aldehyde dehydrogenase (ALDH) immediately metabolizes the reactive aldehyde into 
the corresponding acid.  
The main physiological role of MAO is the degradation of endogenous monoamine 
neurotransmitters and dietary amines, such as tyramine, that, if not properly catabolized, may 
cause hypertensive crises [106]. MAO-A preferentially catalyzes the oxidative deamination of 
norepinephrine and serotonin (5-HT) whereas MAO-B has major affinity for 
phenylethylamine and benzylamine [90]. Thus, MAOs are important to control the turnover 
of these amines [90]. Moreover, in peripheral tissues, MAO prevents the entry of biogenic 
amines in the blood by catabolizing them [107]. Likewise, it has been shown that MAO also 
acts as a metabolic barrier in the microvessels and blood-brain barrier by preventing the 
entrance of false and potentially toxic neurotransmitters [107]. 
Shih et al. have shown that MAO-A and MAO-B knockout (KO) mice display 
differences in neurotransmitter metabolism and behavior [108]. They observed that MAO-A 
KO mice had elevated levels of serotonin, norepinephrine and dopamine in the brain and 
manifest aggressive behaviour. On the other hand, no aggression was observed in MAO-B 
KO mice that displayed only increased levels of phenylethylamine. Both MAO-A and MAO-
B KO mice show increased reactivity to stress. It has been also demonstrated that MAO is 
important during development [108]. Studies in MAO-A KO mice also confirmed that 
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maintenance of serotonin levels is important for the normal development of thalamocortical 
axons and the aggregation of neurons to form barrels. 
4.4.3 Tissue distribution and localization 
It is known that both MAO-A and MAO-B are tightly associated with the OMM 
However, a small portion of these isoforms is also associated with microsomal fractions 
[109]. MAO-A is expressed before MAO-B during development, but levels of the latter are 
known to increase remarkably in the brain after birth [104]. MAO is present in most 
mammalian tissues but the proportion of two isoforms varies from tissue to tissue [104]. The 
distribution of MAO in various tissues of different species has been investigated by use of 
specific inhibitors, immunohistochemistry, enzyme autoradiography and in situ hybridization 
[109]. In the brain, MAO-A has been prevalently found in noradrenergic neurons whereas 
MAO-B has been detected in serotoninergic and histaminergic neurons and in glial cells [90]. 
Regarding peripheral tissues, mainly MAO-B has been found in liver, platelets and kidney 
while MAO-A was present in placenta, liver, intestine and thyroid gland. Human heart 
contains predominantly MAO-A, but MAO-B is also present [90]. In mouse cardiomyocytes, 
MAO-B is the predominant isoform while, in contrast, rat cardiomyocytes express more 
MAO-A [90].  
4.4.4 Monoamine oxidases inhibitors as therapeutic agents 
MAOs catalyze the oxidative deamination and the byproducts of this reaction include 
several chemical species with neurotoxic potential, such as HβOβ, ammonia and aldehydes 
[110]. In the past years, it has been well documented that these flavoenzymes contribute to 
mitochondrial dysfunction and neurodegenerative diseases in both patients and animal models 
[111]. Moreover, MAOs are also involved in numerous other pathologies, in particular 
neuronal and psychiatric disorders [108, 111]. Development of MAO inhibitors started 
receiving attention with the serendipitous finding of antidepressant effects in patients treated 
with iproniazid, a hydrazine-based anti-tubercular agent structurally similar to isoniazid 
[104]. Up to date several MAO inhibitors have been developed and can be classified in three 
groups as stated below: 
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 Irreversible and non-selective inhibitors, such as phenelzine, pargyline and 
tranylcypromine; 
 Irreversible and selective inhibitors, such as selegiline for MAO-B and clorgyline 
for MAO-A; 
 Reversible and selective MAO inhibitors, such as moclobemide for MAO-A and 
safinamide for MAO-B. 
MAO inhibitors have been used for decades for the treatment of depression. The 
antidepressant properties result from selective MAO-A inhibition in the central nervous 
system, which leads to increased brain levels of dopamine, noradrenalin and serotonin [11β]. 
Some of the non-selective irreversible inhibitors, such as phenelzine and tranylcypromine, are 
still in clinical use along with the reversible MAO inhibitors moclobemide, befloxatone, 
toloxatone and safinamide [104]. As levels of MAO-B are increased in patients with 
Parkinson’s disease, MAO-B inhibitor selegiline has been used as a dopamine sparing agent 
[111, 11γ]. Some side-effects of these drugs include liver toxicity, hypertensive crises and 
haemorrhage [90]. Hydrazine-derived inhibitors were highly associated with liver toxicity, 
but this side-effect was avoided with the development of non-hydrazine compounds [104]. 
Irreversible MAO-A inhibitors may cause “cheese effect” which even led to death in some 
cases [104, 106]. This side-effect occurs when tyramine and other sympathomimetic amines 
ingested with food are not degraded in the intestines. They are therefore able to enter the 
circulation and potentiate sympathetic cardiovascular activity by triggering the release of 
noradrenaline [11γ]. Although this side-effect represents a major drawback, this problem was 
resolved by using reversible MAO-A inhibitors such as brofaromine, caroxazone, 
moclobemide, toloxatone and minaprine. In addition to these, safinamide, a reversible MAO-
B inhibitor, was recently licensed by EMA (Emergency medical assistant licensing board) for 
the treatment of Parkinson’s disease in combination with L-DOPA or with other anti-
Parkinson drugs in mid-to advanced-stage fluctuating patients [114].  
4.4.5 Monoamine oxidases in cardiovascular diseases 
MAO has been extensively studied in the brain but it is only recent that the role of these 
flavoenzymes is emerging also in relation to cardiac pathophysiology. Parini’s group was the 
first to demonstrate that MAO-A is an important source of ROS in the myocardium [115]. 
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They showed that MAO-A induced ROS formation is able to trigger signaling pathways that 
are receptor-independent and lead to cell proliferation and hypertrophy or apoptosis. 
Moreover, another study from the same group demonstrated that incubation of 
cardiomyocytes with serotonin led to an increase in ROS production and hypertrophy that 
involved the activation of extracellular signal regulated kinase (ERK) 1/β in a MAO-A 
dependent manner [115, 116]. It was further demonstrated that hypertrophy induced by 
serotonin requires both MAO-A activity and receptor-mediated effects [115]. Indeed, 
serotonin receptor-mediated effect is required for the phosphorylation of ERK1/β whereas 
MAO-generated HβOβ is necessary for the translocation of ERK into nucleus [115]. 
Kaludercic et al. provided an important evidence of the contribution of MAO-A in 
maladaptive remodeling and myocardial dysfunction in hearts subjected to hemodynamic 
stress [117]. They further showed that triggering MAO-A activity leads to increased ROS 
formation, oxidative stress, mitochondrial dysfunction, caspase activation and apoptosis in 
cardiomyocytes (Figure 9). In this study, clorgyline was used as a MAO inhibitor and no side-
effects were observed in control mice. Moreover, the effect of genetic deletion of MAO-A in 
cardiovascular setting was further characterized using mice expressing a dominant-negative 
MAO-A (MAOneo). After 9 weeks of transverse aortic constriction (TAC) wild type (WT) 
hearts displayed greater chamber dilation and impairment in LV function accompanied by 
increased cardiac fibrosis whereas MAOneo mice showed a complete protection against TAC-
induced cardiac remodeling. In contrast, another study showed that MAO-A KO mice 
performed worse after aortic banding [118]. This discrepancy could be due to different 
genetic models used in these studies or due to differences in the severity of the aortic banding 
used to induce hypertrophy and heart failure. 
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Figure 9. MAO-induced ROS formation and LV dysfunction in the heart. Stress stimuli such as 
pressure-overload can trigger hyperadrenergic activation leading to increased availability of 
catecholamines for MAO-dependent degradation. Consequently, increased HβOβ formation can 
directly influence LV remodeling and myocardial function, but it may also target mitochondria 
resulting in permeability transition pore opening and ROS induced ROS release. Moreover, other 
products of these flavoenzymes, such as aldehydes and ammonia, may also participate and exacerbate 
these processes. LV: left ventricle, ROS: reactive oxygen species, MAO: monoamine oxidase. From 
Kaludercic et al., β011 [110] 
A genetic expression profile study reported that MAO-A expression is increased in 
pathological cardiac hypertrophy and heart failure in rats, but not in physiological 
hypertrophy induced by exercise [119]. The role of MAO-B has also been documented in 
pressure overload induced heart failure [1β0]. In these mice, MAO-B−/− mice displayed 
reduced cardiac oxidative stress, LV remodeling and apoptosis. Furthermore, absence of 
MAO-B activity in those hearts completely prevented LV dilation/pump failure [1β0]. MAO-
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dependent aldehyde production is also shown to be detrimental for mitochondrial function 
suggesting that these flavoenzymes not only act as ROS sources but are also producing toxic 
aldehydes that are injurious for heart [1β0-1ββ]. On the other hand, catecholamine cycling 
was also improved in mice lacking MAO-A or MAO-B activity. Indeed, both norepinephrine 
and dopamine degradation were increased in failing hearts due to MAO activation, and its 
inhibition led to improved neuronal pools and availability of these catecholamines [117, 1β0]. 
Studies employing genetically modified mice show that MAO-A-/- and MAO-B-/- 
display a slight reduction in contractility/relaxation, although fractional shortening and 
ejection fraction remain unchanged when compared to WT mice [117, 1β0]. In contrast, 
another study demonstrated that MAO-A-/- mice display cardiomyocyte hypertrophy and LV 
dilation at baseline, although LV dysfunction was absent and no hemodynamic alterations 
were observed [118]. Since MAO deletion in these mice is global and constitutive, it is likely 
that changes in function and morphology at baseline are due to excessive catecholamine 
build-up from birth. This issue could be better evaluated using conditional cardiomyocyte-
specific MAO-A−/− or -B−/− mice. Notably, pharmacological MAO inhibition does not have 
any effects on basal cardiac structure or function. 
Several studies have also investigated the role of MAO in ischemia/reperfusion (I/R) 
injury [1βγ, 1β4]. MAO inhibition with both clorgyline and pargyline remarkably reduced 
infarct size in an in vivo rat model of I/R injury [1βγ]. Another independent study also 
showed that pargyline completely prevented I/R induced injury in isolated Langendorff 
perfused mouse hearts [101]. It has been also demonstrated that MAO-A generated ROS in 
I/R is responsible for sphingosine kinase inhibition, ceramide accumulation and S1P 
(sphingosine-1-phosphate) degradation in cardiac myocytes thereby leading to mitochondria-
mediated apoptosis [1β5].  
The significant role of MAO in generating ROS formation and cardiac dysfunction is 
also supported by in vitro and in vivo models of MAO overexpression [1β6]. Cardiomyocyte 
specific overexpression of MAO-A in mice led to dramatic loss of cardiomyocytes (around 
50%), increased fibrosis and ventricular failure [1β6]. Moreover, these hearts displayed p5γ 
accumulation and reduced levels of PGC-1α (peroxisome proliferator-activated receptor-Ȗ 
coactivator-1α), a master regulator of mitochondrial biogenesis. These changes were 
accompanied by excessive HβOβ formation, reduced ATP levels and mitochondrial 
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dysfunction [1β6]. Recent work has linked these flavoenzymes with lysosomal dysfunction 
both in vitro and in vivo [1β7]. MAO-A dependent ROS generation blocked autophagic flux 
with accumulation of LCγII, p6β, and ubiquitylated proteins, leading to mitochondrial fission 
and cardiomyocyte necrosis. These effects are likely due to MAO-A induced inhibition of 
nuclear translocation of TFEB (transcription factor-EB), a master regulator of autophagy and 
lysosome biogenesis [1β7]. 
The involvement and the pivotal role of MAO in cardiovascular injury highlighted by 
these studies prompt the question whether MAOs could play a role in the oxidative stress and 
cardiac dysfunction triggered by hyperglycemia. Moreover, the fact that these enzymes can 
be targeted pharmacologically makes it tempting to hypothesize that their inhibition might 
represent an attractive therapy for the treatment of diabetic cardiomyopathy. This concept is 
supported by recent work showing the protective efficacy of MAO inhibition on diabetes-
induced cardiac dysfunction [1β8]. However, the mechanisms linking MAO activity with 
mitochondrial dysfunction, ROS formation, inflammation and adverse remodeling are still far 
from being elucidated. In addition, it remains an open question whether MAO-dependent 
ROS generation might affect the crucial cross-talk between mitochondria and ER that occurs 
in diabetic conditions and leads to the impairment in ER homeostasis. 
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4.5 ENDOPLASMIC RETICULUM STRESS  
ER is a network of tubules in the cytoplasm essential for the synthesis, folding and 
processing of secretory and transmembrane proteins. In order to maintain ER homeostasis, a 
balance between ER protein load and folding capacity of this organelle must be achieved. 
However, under several physiological and pathological conditions this balance is disrupted, 
resulting in the accumulation of mis/unfolded proteins, a condition known as ER stress. 
Under these conditions, ER activates a signaling network to maintain its homeostasis known 
as unfolded protein response (UPR). When the UPR is unable to re-establish the balance 
between protein load and folding capacity, it causes cell death and dysfunction [1β9]. In the 
past decade, ER stress has been associated with several cardiovascular complications and 
neurodegeneration [1γ0].  
4.5.1 Unfolded protein response 
The UPR maintains ER homeostasis with the following three distinct functions: (i) 
attenuation of protein translation to reduce ER protein load, (ii) upregulation of molecular 
chaperones to increase the folding capacity of ER, and (iii) activation of ER-associated 
protein degradation (ERAD) pathway to remove the accumulated misfolded proteins and 
prevents them from forming toxic protein aggregates [1β9]. The UPR activates signaling 
pathways through three major transmembrane proteins: protein kinase R-like ER kinase 
(PERK), the inositol-requiring kinase-1 (IRE-1) and the activating transcription factor 6 
(ATF6) (Figure 10) [1β9]. In normal conditions, ER chaperone binding immunoglobulin 
protein (BiP), also known as 78 kDa glucose-regulated protein (GRP78), is bound to the ER 
luminal domain of PERK, IRE1 and ATF6 thereby keeping them inactive [1γ1]. However, 
accumulation of misfolded proteins causes BiP/GRP78 to dissociate from these three ER 
sensors and translocate to misfolded protein, leading to the activation of all three UPR 
branches.  
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4.5.1.1 Protein kinase R-like ER kinase  
When GRP78 dissociates from PERK, it allows this transmembrane protein to dimerize 
facilitating its trans-autophosphorylation. PERK is then activated and phosphorylates the 
eukaryotic translation initiation factor βα (eIFβα) on serine 51 (Figure 10) [1γβ]. This 
phosphorylation event downregulates cap- or eIFβα- dependent translation, thus attenuating 
global mRNA translation [1γγ]. This helps ER to reduce its protein load and favors cell 
survival. When general translation is inhibited, PERK/eIFβα stimulates translation of specific 
proteins, including activating-transcription factor 4 (ATF4), C/EBP homologous protein 
(CHOP) and growth arrest and DNA damage γ4 (GADDγ4) [1β9]. It has been also 
demonstrated that PERK can phosphorylate nuclear factor (erythroid-derived β)-like-β factor 
(Nrfβ), causing it to translocate to the nucleus and activate the expression of anti-oxidant 
genes in response to oxidative stress [1γ4]. Therefore, this UPR signaling pathway acts to 
preserve redox balance during ER stress through activation of ATF4 and Nrfβ. 
4.5.1.2 Inositol-requiring kinase-1 
The IRE1 exists in two isoforms, namely IRE1α and IRE1ȕ, but UPR is mainly 
governed by the IRE1α isoform. This enzyme functions as both kinase and endoribonuclease 
[1γ0, 1γ5]. Like PERK, IRE1α also dimerizes and undergoes trans-autophosphorylation, 
which activates its endoribonuclease activity. Upon activation, IRE1α endoribonuclease 
splices β6-nucleotide intron from X-box-binding protein 1 (XBP1) mRNA, yielding an 
activated spliced form of this protein (Figure 10). The spliced XBP1 translocates to the 
nucleus and binds to the promoter region of ERSEs (ER stress response elements) activating 
the transcription of several ER chaperones and proteins involved in the ERAD machinery 
[1γ6]. IRE1α branch is also known to recruit the ASK1 (apoptosis signal-regulating kinase 1), 
caspase-1β and TRAFβ (tumor necrosis factor receptor-associated factor β) and thus activates 
JNK (jun N terminal kinase) pathway [1γ7]. Therefore, this branch of UPR regulates 
chaperone induction and ERAD pathway. 
4.5.1.3 Activating transcription factor 6 
In mammals, ATF6 protein exists in two isoforms, namely ATF6α and ATF6ȕ. This 
transcription factor has golgi localization sequence [1γ8]. In normal conditions, ATF6 is 
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resident in the ER via an interaction with GRP78, but under ER stress conditions this 
interaction is disrupted causing ATF6 to translocate to golgi (Figure 10) [1γ8]. Once there, 
ATP6 is cleaved, first by site 1 protease and then in the intramembrane region by SβP, 
yielding a 50 kDa ATF6 protein which then translocates to the nucleus [1γ5]. ATF6 acts a 
transcriptional activator of genes involved in ERAD, lipid biosynthesis, protein folding and 
ER expansion [1γ8].  
 
Figure 10. UPR pathway in the ER. ER stress activates three branches of UPR, namely ATF6, 
PERK and IRE1α. ATF6 translocates to golgi upon activation, where it is cleaved by proteases and 
yields a 50 kDa fragment, which then translocates to the nucleus and activates several ER stress genes. 
PERK and IRE1α undergo trans-autophosphorylation and activate the downstream eIFβα and XBP1 
pathways, respectively. This leads to the inhibition of global translation but activates specific genes 
including ATF4 and CHOP to maintain the ER homeostasis. UPR: unfolded protein response, ER: 
endoplasmic reticulum, ATF6: activation transcription factor 6, PERK: protein kinase R-like ER 
kinase, IRE1α: inositol-requiring kinase-1α, eIFβα: eukaryotic translation initiation factor βα. From 
Inagi et al., β014 [1γβ] 
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4.5.2 Contribution of the unfolded protein response to diabetic cardiomyopathy 
Diabetic cardiomyopathy is associated with alterations in both intracellular Caβ+ 
homeostasis and metabolism, which together with increased protein synthesis can induce ER 
stress and consequently trigger the UPR. Several studies reported the upregulation of 
BiP/GRP78, accompanied with the activation of PERK and IRE1α pathway in both T1D and 
TβD animal models. Moreover, Dally et al. showed that upregulation of XBP1 and GRP78 
along with sarco/ER Caβ+ ATPase (SERCA) occurs in hearts from patients with diverse 
cardiomyopathies [1γ9]. ER stress is also associated with the activation of caspase-1β in 
STZ-induced model of T1D, leading to myocardial apoptosis and thus contributing to the 
pathogenesis of diabetic cardiomyopathy [140]. Several studies indicate that ER stress is both 
a trigger and a consequence of autophagy in diabetes. Under conditions leading to ER stress, 
Caβ+ release from ER can inhibit the activity of mammalian target of rapamycin complex 1 
(mTORC1) via activation and phosphorylation of AMPK [141]. Inhibition of mTORC1 is 
proposed to facilitate autophagy [14β]. On the other hand, it has been demonstrated that 
restoration of autophagy alleviates obesity-induced ER stress [14γ, 144]. Chemical 
chaperones, such as 4-phenyl butyric acid and tauroursodeoxycholic acid (TUDCA), have 
been shown to reduce ER stress in TβD mice [145]. These chaperones also prevented 
apoptosis in cardiomyoblasts treated with high glucose [14γ]. Moreover, inhibition of IRE1α 
activity in STZ-induced T1D blocked ER stress and CHOP-mediated apoptosis thereby 
preventing cardiac damage [146]. Collectively, all these studies demonstrate the important 
role of ER stress in the development and progression of diabetic cardiomyopathy.  
Although several studies have been conducted in order to understand the role of ER 
stress in diabetic cardiomyopathy, it still remains to be elucidated how the cell decides 
between survival and death following UPR activation. It also remains to be elucidated to what 
extent these UPR pathways are involved in the pathophysiology of diabetic cardiomyopathy. 
A better understanding of these questions might provide us with new targets for drug 
discovery and therapeutic intervention. 
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4.6 FIBROSIS 
Fibroblasts constitute the most numerous cell population in the myocardium and are 
found in all vertebrate organisms. They are responsible for the synthesis of a variety of 
extracellular matrix (ECM) components, including multiple collagen isoforms, as well as 
fibronectin, and thus play a prominent role in defining cardiac structure and function [147]. 
Fibroblasts are responsible for the development of fibrosis in the heart as well as in other 
organs [148]. Upon injury, cardiac fibroblasts within the connective tissue convert to their 
activated form, often known as myofibroblasts, and secrete elevated levels of ECM proteins 
to promote a pro-fibrotic environment ultimately leading to distorted organ architecture and 
function [149]. Fibrosis is associated with the majority of cardiovascular diseases in 
experimental animal models and humans [150]. Increased ECM synthesis and decreased 
degradation result in increased mechanical stiffness and diastolic dysfunction in the heart. In 
addition to this, increased ECM deposition between the layers of cardiac myocytes also 
disturbs their electrical signaling resulting in impaired cardiac contraction.  
Fibrosis may occur in two forms, reactive interstitial fibrosis or replacement fibrosis 
[151]. Reactive interstitial fibrosis progresses without cardiomyocyte loss in pressure 
overloaded hearts, in order to preserve the pressure generating capacity of the heart [15β]. 
However, it is believed that reactive interstitial fibrosis later develops into a state of 
replacement fibrosis causing cardiomyocyte hypertrophy and death [15β]. Indeed, 
cardiomyocyte apoptosis and replacement fibrosis have been documented in animal models of 
acute myocardial infarction [15β].  
In vitro, high glucose stimulates fibroblast proliferation, promotes myofibroblast 
transdifferentiation and activates transcription and secretion of ECM proteins [15γ, 154]. It is 
demonstrated that high glucose can enhance the synthesis of collagen III, both at mRNA and 
protein levels, in human skin fibroblasts and increase the cell proliferation in human cardiac 
myofibroblasts [15γ, 155]. Moreover, high glucose treatment increas the deposition of type I 
collagen in adult rat cardiac fibroblasts [156]. It has been proposed that high glucose might 
induce fibrosis via activation of angiotensin II, TGF-ȕ signaling and ROS generation 
pathways [157]. However, it appears that hyperglycemia per se is not responsible for 
diabetes-associated cardiac fibrosis, but rather it is the inflammation and ROS formation that 
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lead to fibrosis [154]. In this regard, it has been demonstrated that renal fibrosis persisted 
despite tight glycemic control in STZ-induced T1D mice [158]. 
Inflammation and fibrosis are tightly linked in diabetic cardiomyopathy. In particular, 
pro-inflammatory cytokine tumor necrosis factor α (TNFα) and growth factor TGF-ȕ have 
been shown to modulate fibroblast phenotype and trigger fibrosis [159]. Incubation of 
fibroblasts with TNFα resulted in cell proliferation and increased collagen synthesis whereas 
TGF-ȕ induced differentiation of cardiac fibroblasts into myofibroblasts [159, 160]. TGF-ȕ is 
upregulated in both T1D and TβD hearts and may mediate pro-fibrotic effects via Smad-
dependent and Smad-independent pathways [154]. In addition to cytokines and growth 
factors, infiltration of inflammatory monocytes/macrophages and mast cell degranulation are 
also known to contribute to the development of cardiac fibrosis [161]. Abolishing 
macrophage accumulation prevented cardiac fibrosis and ameliorated diastolic dysfunction in 
hypertensive rats [161]. Cardiac mast cells may induce cardiac hypertrophy and fibrosis by 
synthesizing and secreting pro-fibrotic and pro-inflammatory factors [161, 16β]. In fact, 
administration of mast cell-stabilizing agent tranilast to pressure overloaded mice reduced 
fibrosis and prevented cardiac damage [16β]. Interestingly, oxidative stress has been shown to 
induce mast cell degranulation [16γ-165]. These studies suggest that targeting ROS 
producing enzymes, inflammation and/or pro-inflammatory cells might be a new strategy to 
prevent myocardial fibrosis. 
Besides inflammation, oxidative stress, AGE/RAGE formation, adipokines and recently 
identified miroRNA-1γγ are also associated with cardiac fibrosis [154]. Using 
pharmacological interventions, several studies have demonstrated the role and contribution of 
oxidative stress in diabetes-associated cardiac fibrosis [154, 166, 167]. In T1D and TβD mice, 
inhibition of oxidative stress with dehydroepiandrosterone, a steroid that possesses multi-
targeted antioxidant properties, reduced interstitial fibrosis, cardiomyocyte hypertrophy and 
improved diastolic function [154, 168].  
AGE/RAGE signaling is known to activate inflammatory genes, crosslink collagens and 
laminins in the extracellular matrix, and stimulate fibroblast proliferation that may increase 
diastolic stiffness and cause diastolic dysfunction [169]. Indeed, inhibition of RAGE activity 
prevented fibrosis and development of cardiac dysfunction in db/db TβD mice [154].  
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Adipokines leptin and adiponectin have also been associated with cardiac fibrosis [154]. 
Leptin is known to induce matrix metalloproteinases in fibroblasts. Its role in cardiomyocytes 
remains controversial since it can exert both hypertrophic and anti-hypertrophic actions [154, 
170, 171]. Adiponectin is an anti-inflammatory agent that exerts anti-fibrotic effects in 
angiotensin II-induced cardiac remodeling and reduced cardiac hypertrophy via AMPK 
signaling in TβD mice [154].  
Several mechanisms by which fibrosis can lead to heart failure have been proposed, 
including reduced ventricular compliance causing HFpEF, atrial fibrillation, increased risk of 
ventricular arrhythmias, diabetes-related perturbation of the reparative response following 
infarction, adverse remodeling and development of post-infarction heart failure [154]. Thus, 
preventing cardiac fibrosis might reduce mortality and morbidity in patients with diabetic 
cardiomyopathy. It appears that novel therapies targeting ROS formation, AGE-mediated 
crosslinking and TGF-ȕ system hold significant promise. 
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4.7 INFLAMMATION 
Emerging evidence indicates that inflammation is a crucial process in adverse 
myocardial remodeling [17β]. A number of clinical and animal studies reported that 
activation of several inflammatory pathways occurs in cardiovascular complications [17β]. 
Inflammation involves the secretion of cytokines, such as chemokines, interferons, ILs, TNFs 
and recruitment of innate immune cells, such as neutrophils, mast cells and 
monocyte/macrophages [17γ]. Prolonged exposure of heart to these inflammatory agents can 
exacerbate myocardial remodeling and lead to myocardial damage [17γ]. Notably, in addition 
to local adverse effects it has been demonstrated that cardiac injury-induced inflammation in 
the heart results in the release of TNFα, IL-1ȕ, IL-18 and growth factor TGF-ȕ into the 
circulation [17γ]. In agreement with this, a recent study reported elevation of these cytokines 
in the serum of diabetic patients suggesting that they might be used as biomarkers to diagnose 
early stage diabetic cardiomyopathy. Early diagnosis of diabetic cardiomyopathy would allow 
for the timely start of treatment, thus attenuating disease progression prior to the onset of 
irreversible complications [174].  
Cytokines can lead to contractile dysfunction and cell death by various mechanisms. 
For instance, cytokines can trigger peroxynitrite formation via iNOS activation [66]. Upon 
stimulation, iNOS produces large amounts of NO that can react with superoxide to form 
peroxynitrite, a species known to cause myocardial contractile failure. Rat hearts perfused 
with cocktail of cytokines, including IL-1ȕ, interferon-Ȗ and TNF-α, resulted in an enhanced 
activity of Nox and iNOS accompanied by increased NO content, superoxide production and 
markers of peroxynitrite formation [175]. The peroxynitrite decomposition catalyst FeTPPS 
(5,10,15,β0-tetrakis-[4-sulfonatophenyl]-porphyrinato-iron[III]), inhibited the decline in 
myocardial function and decreased perfusate nitrotyrosine levels indicating that cytokine-
induced myocardial contractile failure is mediated by peroxynitrite [175].  
Another cytokine-mediated mechanism involves the regulation of SERCA expression 
and activity by oxidation/nitration leading to impaired ER function [66]. It is also known that 
cytokines can increase the synthesis of ECM in the heart leading to fibrosis and ultimately 
cardiac dysfunction as discussed above. Indeed, TNFα inhibition with a monoclonal antibody 
prevented intra-myocardial inflammation, fibrosis and cardiac damage in STZ-induced T1D 
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rats [176]. Importantly, clinical studies demonstrated that recombinant human IL-1 receptor 
antagonist Anakinra improved glycaemia and ȕ-cell secretory function and reduced markers 
of systemic inflammation in patients with T1D and TβD, suggesting that antagonizing the IL-
1 system may prevent or delay the onset of diabetes [177, 178].  
Expression of pro-inflammatory cytokines is under the control of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB), a transcription factor activated in 
myocarditis, congestive heart failure and cardiac hypertrophy [179]. Several stimuli may 
induce the activation of this transcription factor including pro-inflammatory cytokines 
themselves, elevated free fatty acid levels in plasma, hyperglycemia, ROS, angiotensin II, 
endothelin-1, toll-like receptors and hyperglycemia-induced AGE formation [66]. It has been 
demonstrated that high glucose can promote NF-κB activity in cultured neonatal rat 
cardiomyocytes through diacylglycerol-PKC signal transduction pathway [10β]. In normal 
conditions, NF-κB resides in the cytoplasm as an inactive heterodimer bound to the inhibitory 
protein IκB [179]. Several stress stimuli induce IκB phosphorylation leading to its 
ubiquitination and proteasome-mediated degradation that releases the NF-κB heterodimer, 
which can then translocate to the nucleus [179]. NF-kB transcription factors bind to 9-10 base 
pair DNA sites (called kB sites) as dimers and induce cytokine gene expression in the 
nucleus. Resveratrol inhibits NF-κB activity by upregulating SIRT1-mediated deacetylation 
of lysine γ10, thus preventing metabolic dysregulation and inflammatory processes in several 
murine models [180]. While the expression of pro-IL-1ȕ and pro-IL-18 is mediated by NF-
κB, their processing to the mature form is mediated by active caspase-1. This caspase is a part 
of inflammasome complex, nucleotide-binding oligomerization domain-like receptors with 
pyrin domain (NLRPγ) [17γ]. Inflammasome is a multiprotein complex necessary for 
caspase-1 activation and amplification of the inflammatory response. Indeed, NLRPγ gene 
silencing therapy ameliorated inflammation, cardiac fibrosis and improved cardiac function in 
high fat diet-induced TβD rats [181]. Recently, it has been proposed that inflammasome 
activation depends on cell-to-cell communication in the heart, including cardiomyocytes, 
fibroblast and innate immune cells [17γ].  
Mitochondrial ROS formation has been identified as an important NLRPγ 
inflammasome activator in cardiac diseases [18β]. The saturated fatty acid palmitate leads to 
the activation of the NLRPγ inflammasome and release of active IL-1ȕ in a mitochondrial 
ROS-dependent manner [18γ]. Fibroblasts have been shown to secrete IL-1ȕ in response to 
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ATP and mitochondrial DNA released from neighboring cells such as cardiomyocytes [17γ, 
181, 184]. In addition to fibroblasts, injured cardiomyocytes also secrete IL-1ȕ and release 
damage-associated molecular pattern molecules, DNA fragments and heat-shock proteins 
which mandate surrounding healthy cardiomyocytes to produce inflammatory factors such as 
IL-1ȕ, IL-18, IL-6, monocyte chemoattractant protein-1 and TNFα [181]. These factors in 
turn activate versatile signaling networks within surviving cardiomyocytes and trigger the 
activation and recruitment of immune cells including macrophages, leukocytes and mast cells 
further exacerbating inflammatory response [181]. Collectively, these studies indicate that 
cross-talk between different cardiac cell populations, including cardiomyocytes, fibroblasts 
and immune cells, plays a very important role in triggering myocardial inflammation, which 
then contributes to reduced contractile function and heart failure in various diseases including 
diabetic cardiomyopathy. 
In summary, diabetic cardiomyopathy is a very complex disease associated with 
structural, functional and metabolic changes in the heart. It is proposed that, not one single 
mechanism, but rather the combination of several mechanisms contributes to the pathogenesis 
of this epidemic disease [γ7, γ9, 66, 185]. From preclinical and animal studies it has become 
clear that oxidative stress and inflammation are central components in triggering and driving 
the pathological processes associated with diabetic cardiomyopathy [γ9, 66]. Mitochondria 
play a critical role in inducing oxidative stress and triggering inflammation via inflammasome 
pathway [γ9, 181, 186]. This notion is more relevant for the heart since cardiomyocytes have 
higher mitochondrial content relative to other cell types, thus making cardiac tissue more 
susceptible to mitochondria-induced damage compared to other organs. This suggests that 
therapeutic interventions targeting mitochondria or preventing mitochondria-induced damage 
may be required to treat patients with diabetes-associated cardiovascular complications.  
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5. AIMS AND HYPOTHESES 
The aim of this study was to investigate the role of MAOs in oxidative stress, 
mitochondrial dysfunction and cardiac damage in T1D. Diabetes-induced derangements and 
protective mechanisms were investigated in the following experimental models: (i) 
mimicking the diabetic conditions with high glucose (HG) and/or pro-inflammatory cytokine 
IL-1ȕ in primary cardiomyocytes in vitro and (ii) using STZ-induced T1D mice in vivo.  
The working hypothesis was that mitochondrial ROS formation plays a central role in 
diabetic cardiomyopathy. Based upon previous work from our laboratory demonstrating the 
involvement of MAO in cardiac pathology, we investigated whether MAOs contribute to 
increased ROS formation and mitochondrial dysfunction in cultured primary cardiomyocytes 
treated with HG and/or IL-1ȕ, a pro-inflammatory cytokine found to be elevated in diabetic 
patients. MAO involvement and contribution were evaluated through a classical 
pharmacological approach, using pargyline as an inhibitor for both MAO-A and MAO-B. We 
further assessed whether MAO activity is involved in the interplay between mitochondria and 
ER and whether MAO-generated ROS contribute to impaired ER homeostasis and activation 
of UPR in this setting.  
Next, we aimed to assess the efficacy of MAO inhibitor pargyline in preventing 
structural and functional changes in T1D hearts in vivo. We hypothesized that MAOs 
contribute to the oxidative stress and diastolic dysfunction occurring in T1D hearts. Diabetic 
cardiomyopathy is associated with cardiac inflammation, mitochondrial ROS formation, 
oxidative stress and fibrosis in, but the exact source of ROS linking these events in the heart 
has not been identified yet. To this aim, we investigated whether MAO activity might be 
involved in the formation of the vicious cycle between mitochondrial ROS and pro-
inflammatory response ultimately leading to fibrosis and LV dysfunction.  
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6. MATERIALS AND METHODS 
6.1 Primary cardiomyocytes isolation and culture 
6.1.1 Isolation and culture of neonatal rat ventricular myocytes 
Neonatal rat ventricular myocytes (NRVMs) were isolated from 1-γ days old Wistar 
rats as previously described [1β0]. Briefly, hearts were excised, cut into smaller pieces and 
left for overnight digestion with β.5% trypsin 10X (Thermo Fisher Scientific) at 4°C in 
Hank’s balanced salt solution (HBSS, Sigma). Next day, tissues were incubated with 0.75 
mg/ml collagenase type II (Thermo Fisher Scientific) in HBSS for 10 min (at β min intervals) 
at γ7°C and cells dissociated by pipetting. Following centrifugation at 1000 rpm for 7 min, 
cells were resuspended in minimum essential media (MEM, Invitrogen) and pre-plated for an 
hour to let cardiac fibroblasts attach to the plastic surface. Plates/coverslips were coated with 
a solution of 0.1% porcine gelatin (Sigma) and incubated at γ7°C for 1 h. The non-adherent 
myocytes were plated in gelatin coated plates at the density of 1x105 cells/ml in MEM 
supplemented with 10% FBS, 1% penicillin/streptomycin, non-essential amino acids, 1 mM 
BrdU. Cells were maintained at γ7°C in presence of 5% COβ. The medium was changed to 
MEM supplemented with 1% FBS after β4 h of plating.  
6.1.2 Isolation and culture of adult mouse ventricular cardiomyocytes 
Adult mouse ventricular myocytes were isolated from the hearts of 1β week old 
C57Bl6/J mice as described previously [1β0]. In brief, mice were injected intraperitoneally 
(i.p.) with 1,000U heparin γ0 min before the isolation procedure to prevent coagulation of 
blood in the arteries. Hearts were quickly excised and the aorta cannulated. Hearts were then 
perfused with perfusion buffer (PB, in mM: NaCl 1β0, KCl 14.75, KHβPO4 0.6, NaβHPO4 
0.γ, MgSO4 1.β, HEPES 10, NaHCOγ 4.6, taurine γ0, BDM 10, glucose 5.5, pH 7.4) for β 
min to remove the blood. Next, hearts were perfused with PB containing 1.β mg/ml 
collagenase type II (Worthington) and 0.05 mg/ml protease type XIV (Sigma) for γ min at β 
ml/min and then for 8 min at1.5 ml/min. After perfusion hearts were placed into 5 ml of PB 
added with 10% FBS and 1β.5 µM CaClβ, cut into smaller pieces and cardiomyocytes 
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dissociated by gentle pipetting. The suspension was filtered through 100 µm mesh, 
centrifuged at 500 g for 1 min and resuspended in PB containing increasing Caβ+ 
concentration. Caβ+ concentration was gradually increased from 0.β5 mM to 1 mM to avoid 
Caβ+ overload and hypercontracture. After each step cardiomyocytes were allowed to 
sediment by gravity. Cells were plated at a non-confluent density of β5,000 rod-shaped 
myocytes/ml on glass coverslips pre-coated with laminin (β0 µg/ml) in MEM with Hank’s 
salts supplemented with 10 mM NaHCOγ, 5% FBS, 1% penicillin/streptomycin, 10 µM 
blebbistatin and kept at γ7°C in presence of β% COβ. After 1h media was changed to MEM 
with Hank’s salts supplemented with 10 mM NaHCOγ, 0.β% BSA, 10 µM blebbistatin, 1% 
insulin-transferrin-selenium (ITS, Thermo Scientific), β mM L-glutamine, β mM L-carnitine, 
5 mM creatine and 5 mM taurine.  
6.2 Treatment of primary cardiomyocytes 
NRVMs and adult cardiomyocytes were treated in culture media with following 
additions: normal glucose (NG, 5 mM), high glucose (HG, β5 mM) or high mannitol (HM β5 
mM, osmotic control) in presence or absence of IL-1ȕ β5 ng/ml (Sigma). To inhibit MAO 
activity cells were pre-treated with 100 µM pargyline (Sigma) for γ0 min. ROS formation and 
mitochondrial membrane potential were measured after 48 h in NRVMs and after γ h of 
treatment in adult cardiomyocytes. ER stress was assessed after 48 h of incubation. 
To induce ER stress, NRVMs were incubated overnight with tunicamycin (1 µg/ml) or 
thapsigargin (1 µM) in presence or absence of ER stress inhibitor TUDCA (100 µM, Sigma). 
To assess the effect of MAO inhibition on ER stress, cells were pre-treated with 100 µM 
pargyline in presence of ER stress-inducers. After overnight incubation, samples were 
collected to assess ER stress markers gene expression or cells were loaded with MTR to 
measure ROS formation in these conditions.  
54 
 
6.3 Measurement of mitochondrial ROS formation  
6.3.1 Assessment of ROS formation with MitoTracker Red 
To measure mitochondrial ROS formation, cells were loaded with β5 nM (NRVMs) or 
β50 nM (adult cardiomyocytes) MitoTracker Red CM-HβXRos (MTR, Thermo Fisher 
Scientific, excitation/emission 579/599 nm), a reduced dye that fluoresces upon oxidation and 
accumulates inside the mitochondria depending on the mitochondrial membrane potential 
(ΔΨm). After γ0 min incubation at γ7°C cells were washed and images were captured using 
fluorescence microscope (Leica TCS SP5). Fluorescence intensity was quantified using Java-
based image processing program ImageJ (NIH). For NRVMs, results were normalized to the 
control values (NG vehicle) and expressed as % vs control. For the adult cardiomyocytes, 
background signal was subtracted from all analyzed regions of interest and results were 
expressed as arbitrary fluorescence units (AU).  
6.3.2 Transfection of neonatal rat cardiomyocytes and assessment of ROS formation 
with HyPer  
Alternatively, ROS formation in NRVMs was measured using genetically encoded 
HβOβ probe HyPer (Evrogen) targeted either to mitochondria or cytosol. HyPer is a 
ratiometric dye with two excitation peaks (maxima at 4β0 nm and 500 nm), and one emission 
peak (maximum at 516 nm). Upon exposure to HβOβ, the excitation peak at 4β0 nm decreases 
proportionally to the increase in the peak at 500 nm, allowing for ratiometric measurement of 
HβOβ. NRVMs were plated in six-well plates at a density of γx105 cells/well and transfected 
with calcium phosphate method. For each transfection, β µg of plasmid (mito-HyPer or cyto-
HyPer) were rapidly mixed with ice cold β50 mM CaClβ in HBSS (β74 mM NaCl, 10 mM 
KCl and 1.4 mM NaβHPO4) and left for 4 min to precipitate. The mixture was added to the 
cells and after 4 h of incubation, cells were washed with PBS and new MEM media was 
added. Transfected cells were used for experiments after 48 h. 
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6.4 Assessment of mitochondrial membrane potential 
To measure the ΔΨm, cells were pre-incubated with β5 nM tetramethylrhodamine 
(TMRM, Thermo Fisher Scientific) in presence of 1.6 µM cyclosporin H. TMRM (excitation 
5γ5 nm and emission 600 nm) is a lyophilic rhodamine dye that accumulates into the 
mitochondria of live cells depending on their ΔΨm. After incubation, cells were analyzed 
under Leica fluorescence microscope and images were captured before and after the addition 
of β.5 µM FCCP (Sigma), a protonophore (H+ ionophore) and uncoupler of oxidative 
phosphorylation, to completely abolish ΔΨm . TMRM fluorescence intensity was analyzed 
using ImageJ and results are expressed ΔF according to the following formula: ΔF = F0/FFCCP, 
where F0= TMRM fluorescence intensity at baseline and FFCCP= fluorescence intensity after 
addition of FCCP. For kinetics experiments, TMRM fluorescence intensity was monitored 
following addition of oligomycin (5 µM) or FCCP (β.5 µM). TMRM fluorescence intensity 
was quantified as described above and data were expressed as % vs the initial value.  
6.5 cDNA synthesis and Real time-PCR 
Total RNA was extracted from NRVMs using TRIzol reagent (Invitrogen), a 
monophasic solution of phenol and guanidine isothiocyanate, according to the manufacturer 
instructions. Reverse transcription reactions were performed using 5 μg of total RNA. After 
addition of dNTP and random hexamer primers to prime the first strand for cDNA synthesis, 
RNA was denatured at 65°C for 5 min and then placed on ice. Superscript III (Invitrogen) 
was added to the mixture which was further incubated at 5β°C for 50 min and 70°C for 15 
min to synthesize cDNA. 
Each PCR reaction was performed in a β0 μl volume combining 10 ng of cDNA, 0.β5 
μM of forward and reverse primers and 10 μl of SYBR green βX PCR master mix 
(Invitrogen). RotorGene γ000 (Qiagen) thermal cycler was used to carry out the real-time 
PCR reaction. The sequences of forward and reverse primers used to detect the expression of 
each gene are listed in Table β. 
Target gene Primer sequence 
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ATF4 
F-5’AATGGATGACCTGGAAACCAγ’ 
R-5’TCTTGGACTAGAGGGGCAAAγ’ 
CHOP 
F-5’AGAGTGGTCAGTGCGCAGCγ’ 
R-5’CTCATTCTCCTGCTCCTTCTCCγ’ 
total-XBP1 
F-5’TGGCCGGGTCTGCTGAGTCCGγ’ 
R-5’ATCCATGGGAAGAGTTCTGGγ’ 
spliced-XBP1 
F-5’CTGAGTCCGAATCAGGTGCAGγ’ 
R-5’ATCCATGGGAAGATGTTCTGGγ’ 
unspliced-XBP1 
F-5’CAGCACTCAGACTACGTGCGγ’ 
R-5’ATCCATGGGAAGATGTTCTGGγ’ 
α-tubulin 
F-5’CAACACCTTCTTCAGTGAGACAGGγ’ 
R-5’TCAATGATCTCCTTGCCAATGGTγ’ 
Table 2. Sequences of primers used for real-time PCR 
6.6 Determination of cell viability 
Resazurin based in vitro toxicology kit (Sigma) was used for determination of cell 
viability. Resazurin is a redox indicator dye that can be added directly to cells in culture. 
Cells convert the dark blue oxidized form of the dye (resazurin) to a red reduced form 
(resorufin). This system is specific for viable cells since non-viable cells rapidly lose 
metabolic capacity and are no longer able to reduce resazurin. Fluorescence intensity was 
recorded with a fluorimeter using 544 nm excitation and 590 nm emission wavelengths to 
assess resorufin formation. This value was normalized to the one obtained from control cells 
treated in the same conditions. Cells were plated in 1β well plates at a density of βx105 
cells/well, and treated with tunicamycin (1µg/ml) or thapsigargin (1µM) in presence or 
absence of pargyline (100 µM). After β4 h of treatment, culture medium was aspirated and 
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another 1 ml of culture medium containing 10% resazurin was added. Fluorescence intensity 
of the supernatant was recorded at the beginning and after β h of incubation with resazurin. 
6.7 Animal model of type 1 diabetes 
All the animal studies were performed using male C57BL6/J mice (6-7 weeks of age 
and at least β0 g in weight; Charles River Laboratories, UK). T1D was induced with STZ (50 
mg/kg/day in citrate buffer pH 4.5) administered intraperitoneally for five consecutive days. 
Mice were then randomized to receive either vehicle or MAO inhibitor pargyline (50 
mg/kg/day) for 1β weeks. Blood glucose levels were measured twice a month using glucose 
meter (OneTouch Ultra β) and mice with blood glucose levels ≥17 mM were considered 
diabetic.  
6.8 Assessment of pressure-volume relationships  
Cardiac function was assessed using MRI-calibrated PV loops in vivo. MRI scan was 
performed as previously described [γ0, γ1] and volumes obtained at end systole and end 
diastole were later used to calibrate hemodynamic data. To acquire PV catheter data, mice 
were quickly anaesthetized using an isoflurane chamber followed by a 70 mg/kg 
intraperitoneal injection of pentobarbital. We monitored the adequacy of anesthesia using 
corneal and withdrawal reflexes. Temperature was maintained at γ7°C with a thermostatically 
controlled heating control unit (Harvard apparatus, Holliston, MA). After endotracheal 
intubation for mechanical ventilation (ventilation frequency 110 breaths per minute with a 
tidal volume of 1.β ml/min; Harvard apparatus, Holliston, MA), mice underwent closed-chest 
catheterization of the left ventricle via the carotid artery. After a stabilization period of 15 
min, pressure and volume data was acquired using a Transonic ADV 500 system (iWorx 1β5 
Systems Inc., NH). Under these conditions, mean heart rate across all groups was γ59.6±9.6 
(SE). PV-loop analysis was performed by a single investigator blinded to subject identity. 
Before PV loop analysis, volumes were smoothed (smoothing kernel of 4 ms), and calibrated 
using the MRI data. Here, the maximum and minimum volumes obtained with the catheter 
were matched to the MRI-derived LV volumes. Summary pressure values and diastolic 
stiffness values were derived using Labscribe β (iWorx 1β5 Systems Inc., NH). 
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6.9  Histology 
Hearts were fixed in 10% formalin overnight, embedded in paraffin and sectioned at 10 
µm thickness. Samples were analyzed for fibrosis and mast cell degranulation using Masson’s 
Trichrome staining and toluidine blue staining, respectively [117]. Before staining, tissue 
sections were deparaffinized, rehydrated through 100%, 95%, 85%, 80% and 70% alcohol 
and washed in distilled water or PBS. 
Fibrosis staining was performed on tissue sections using Masson’s Trichome kit 
(Sigma) following manufacturer instructions. In this protocol, collagen and muscle fibers 
stain differentially when treated sequentially with biebrich scarlet-acid fuchsin, 
phosphomolybdic-phosphotungstic acid solution and aniline blue. Cytoplasm and muscle 
fibers stain red whereas collagen displays blue coloration as shown in Figure 11A. 
Photomicrographs of the sections were evaluated for interstitial collagen fractions using 
computer-assisted image analysis systems (Adobe Photoshop). 
 
 Figure 11. Masson’s Trichome and toluidine blue staining. (A) Cardiac muscle fibers stained in 
red and collagen stained in blue following Masson’s Trichome staining on paraffin embedded 
sections. (B) Red arrows point toward intact mast cells whereas black arrow indicate actively 
degranulating mast cell. 
Toluidine blue stains mast cells red-purple (metachromatic staining) and the 
background blue (orthochromatic staining) as shown in Figure 11B. Briefly, deparaffinized 
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and rehydrated tissue sections were stained in toluidine blue 0.1% solution at pH β.γ for γ 
minutes. Slides were than washed in distilled water, quickly dehydrated through 95% and 
100% ethanol, cleared in xylene (γ x 15 min) and mounted with Permount. Mast cell density 
was determined by counting the total number of mast cells per field. Mast cell degranulation 
was expressed as the number of degranulating mast cells normalized to total number of mast 
cells. 
6.10 Western blot  
Isolated cardiomyocytes or heart tissue were homogenized in lysis buffer (1% NP-40, 
50 mM Tris HCl, 150 mM NaCl and β mM EDTA, pH 7.5) containing phosphatase 
(PhosSTOP, Roche) and protease inhibitors (cOmplete mini protease inhibitor cocktail, 
Roche). Homogenized samples were centrifuged at 1γ,000 x g for 15 min at 4°C and the 
pellet was discarded. Protein concentration was determined using BCA Protein Assay Kit 
(Pierce) following the manufacturer’s protocol. To denature and solubilize the proteins, 1X 
NuPage sample buffer (Novex) and ȕ-mercaptoethanol (γ%) were added to the samples. 
Samples were boiled at 100°C for 10 minutes. Then they were loaded on the gel or aliquoted 
and stored at -β0°C.  
Proteins were separated on 4-1β% gradient SDS-PAGE (NuPage) using MES running 
buffer (50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.γ) at 150 V and 
transferred to the nitrocellulose membrane (Bio-rad) overnight using transfer buffer (β5 mM 
Tris, 19β mM glycine, 10% methanol, pH 8.0) at 150 mA . Once the transfer was carried out, 
the membrane was incubated with Red Ponceau dye (EuroClone) to stain all the proteins on 
the membrane. Next, membrane was destained with NaOH, washed and saturated using a 
blocking solution composed of 50 mM Tris-HCl, β mM CaClβ, 85 mM NaCl, 5% BSA, pH 
8.0. After 1 h of blocking at room temperature, blots were incubated at 4°C overnight with 
primary antibody diluted in blocking solution. Antibodies used in this study to detect proteins 
of interest are listed in Table γ.  
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Primary antibody Manufacturer Dilution 
Anti-MAO-A Abcam (ab1β6571) 1:1000 
Anti-MAO-B Sigma (AV4γ557) 1:1500 
Anti-GRP78 Abcam (abβ1685) 1:1000 
Anti-phospho IRE1α Novus (NB100-βγβγ) 1:500 
Anti-4-HNE Abcam (ab46545) 1:1000 
Anti-ATF4 (CREB-2) Santa Cruz (SC-β00) 1:1000 
Anti-GADD34 Santa Cruz (SC-8γβ7) 1:1000 
Anti-GAPDH Sigma (G8795) 1:5000 
Anti-α-Tubulin Abcam (ab4074) 1:1000 
Anti-β-Actin Sigma (Aβββ8) 1:1000 
Table 3: List of primary antibodies used in the study 
Following incubation with primary antibodies, membranes were washed three times for 
10 min with the washing buffer (50 mM Tris-HCl, 85mM NaCl, 0.1% Tween β0, pH 7.4). 
Secondary antibodies were diluted in blocking solution and incubated with the membrane for 
1 hour at room temperature. Secondary antibodies used were: 
Anti-mouse (Santa Cruz), dilution 1:5000 
Anti-rabbit (Santa Cruz), dilution 1:5000 
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Secondary antibody is conjugated to reporter enzyme HRP (horseradish peroxidase). 
After incubation with secondary antibody, membrane was washed three times (10 min each). 
Protein bands were revealed using LiteAblot luminol solutions (EuroClone). Bands were 
detected using KODAK Image station 4000 MM PRO and analyzed using Gel-Pro software. 
6.11 Statistical analysis 
All values are expressed as mean ± SEM. Comparison between groups was performed 
by one-way or two-way ANOVA, followed by a Tukey’s post hoc multiple comparison for 
normally distributed data and non-parametric Dunn’s test for data that was not normally 
distributed. Comparisons between two groups were performed using non paired two-tailed 
Student’s t-test. A value of p<0.05 was considered significant. 
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7.  RESULTS  
7.1  HG and IL-1β induce ROS formation in primary cardiomyocytes in a 
MAO-dependent manner 
Hyperglycemia and inflammation are tightly associated with diabetic cardiomyopathy 
[γ7, 187, 188]. It has been shown that over-production of pro-inflammatory cytokines, such 
as TNF-α and IL-1ȕ, provoke cardiomyocyte apoptosis and cardiac remodeling through 
activation of various cell death pathways. Moreover, patients with cardiomyopathy show 
elevated levels of IL-1ȕ produced by endothelial cells and myocytes [189, 190]. Thus, to 
mimic diabetic conditions in vitro more realistically, NRVMs were treated with HG and pro-
inflammatory cytokine IL-1ȕ alone or in combination, and ROS levels were initially assessed 
with MTR after 48 h. To rule out the effect of hyperosmolarity induced by HG, identical 
concentrations of mannitol were added to cells cultured with NG. HG lead to a mild but 
significant increase in ROS formation, whereas mannitol treated NRVMs did not show any 
changes when compared to NG cultured cells (Figure 1β). Interestingly, the combination of 
HG and IL-1ȕ led to a further dramatic increase in ROS formation when compared to HG or 
IL-1ȕ treatment alone, indicating a synergistic effect of these stimuli in inducing 
mitochondrial ROS formation. To investigate whether MAO contributes to increased ROS 
formation in these conditions, we pre-treated cardiomyocytes with pargyline, an irreversible 
inhibitor of both MAO-A and MAO-B. MAO inhibition abolished ROS formation induced by 
both HG alone and by combination of HG and IL-1ȕ, suggesting that both stimuli induce 
ROS formation in a MAO-dependent manner.  
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Figure 12. Effects of HG and pro-inflammatory cytokine IL-1β on ROS formation. 
Mitochondrial ROS formation determined by MTR in isolated NRVMs cultured with NG (5 mM), HG 
(β5 mM) and HM (β5 mM) for 48 h, in the absence or presence of IL-1ȕ (β5 ng/ml), and with or 
without pargyline (100 µM). *p<0.05 vs NG vehicle; #p<0.01 vs HG vehicle and §p<0.05 HG-IL1ȕ 
vehicle. NG: normal glucose, HG: high glucose, HM: high mannitol, ROS: reactive oxygen species, 
IL-1ȕ: interleukin-1ȕ, MTR: MitoTracker Red CMHβX-ROS, NRVMs: neonatal rat ventricular myocytes. 
The initial evidence of MAO-reduced ROS formation was obtained by means of MTR 
fluorescence. However, this fluorescent probe presents some limitations. For instance, (i) its 
accumulation in the mitochondrial matrix is ΔΨm-dependent and might be influenced by the 
changes in ΔΨm induced by different treatments [191], (ii) it is not specific for single ROS 
species and (iii) it can get oxidized in the cytosol before entering the mitochondrial matrix. 
To overcome these limitations and to further confirm our results obtained with MTR, we used 
a genetically encoded probe HyPer to measure ROS formation in cells treated with HG and 
IL-1ȕ. HyPer has several advantages over MTR; for instance, it can be targeted to different 
subcellular compartments, it is specifically oxidized by HβOβ and it is more sensitive, thus 
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making it a more suitable probe to assess MAO-dependent HβOβ formation in our 
experimental conditions.  
Using HyPer constructs targeted either to the mitochondria or cytosol (Figure 1γA), we 
observed that HG-treated NRVMs displayed a significant increase in both mitochondrial and 
cytosolic HβOβ formation and, similarly to results obtained with MTR, co-treatment with HG 
and IL-1ȕ led to an even higher increase in HβOβ levels (Figure 1γB). Moreover, MAO 
inhibitor pargyline prevented this increase in HβOβ formation, further confirming that HG and 
IL-1ȕ induced ROS formation in a MAO dependent manner. Measurements obtained with 
HyPer also indicate that MAO-dependent ROS formation induced by HG and IL-1ȕ is not 
only limited to mitochondria but it also occurs in the cytosol. However, it still remains to be 
elucidated whether ROS formation might occur with different kinetics in these compartments 
as reported previously for MAO-dependent ROS generation [19β].  
 
Figure 13. Compartment-specific H2O2 formation following HG and IL-1β treatment of NRVMs. (A) Fluorescent images of NRVMs transfected with genetically encoded HβOβ sensitive probe HyPer, targeted to mitochondria or to the cytosol. (B) HβOβ formation measured after 48 h of 
treatment with NG (5 mM), HG (β5 mM) in presence or absence of IL-1ȕ (β5 ng/ml), with or without 
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pargyline (100 µM). *p<0.05 vs NG vehicle, #p<0.05 vs HG vehicle and §p<0.05 vs HG-IL1ȕ. NG: 
normal glucose, HG: high glucose, IL-1ȕ: interleukin-1ȕ, NRVMs: neonatal rat ventricular myocytes. 
We next examined whether the same effects could be observed in adult mouse 
cardiomyocytes. Neonatal hearts are relatively more dependent on glucose as a preferred 
substrate, whereas adult hearts rely on fatty acid oxidation for the generation of ATP 
necessary to support cardiac contraction and relaxation [19γ, 194]. Consequently, neonatal 
cells might be less susceptible to HG-induced derangements as compared to adult 
cardiomyocytes.  
Indeed, HG showed a more prominent effect in adult cardiomyocytes leading to a ~β 
fold increase in ROS formation after only β hours of incubation (Figure 14). However, no 
further increase in oxidative stress was observed with the co-treatment of HG and IL-1ȕ. 
Pargyline treatment reduced ROS formation in both conditions, further confirming that MAO 
plays a pivotal role in HG and IL-1ȕ induced oxidative stress. Taken together, these results 
indicate a crosstalk between MAO-generated oxidative stress, inflammation and 
mitochondria. 
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Figure 14. Mitochondrial ROS formation in isolated adult mouse cardiomyocytes following HG 
and IL-1β exposure. Cells were treated with NG (5 mM), HG (β5 mM) in presence or absence of IL-
1ȕ (β5 ng/ml), with or without pargyline (100 µM) for β h. Mitochondrial ROS formation was 
measured by MTR. *p<0.05 vs NG vehicle; #p<0.05 vs HG vehicle, §p<0.05 vs HG+IL-1ȕ vehicle. 
NG: normal glucose, HG: high glucose, ROS: reactive oxygen species, IL-1ȕ: interleukin-1ȕ, MTR: 
MitoTracker Red CMHβX-ROS 
In order to elucidate whether enhanced HβOβ generation observed in our conditions was 
due to an increase in MAO protein expression, we performed Western blot to assess the 
abundance of MAO-A, the main isoform present in NRVMs. However, we did not observe 
any significant changes in MAO-A protein expression between different experimental groups 
(Figure 15).  
67 
 
 
Figure 15. MAO-A protein expression in NRVMs treated with HG and/or IL-1β. Representative 
blots are shown for MAO-A protein expression in NRVMs treated with different conditions after 48 h. 
The quantification of band intensity is shown normalized to ȕ-actin and α-tubulin, respectively. MAO: 
monoamine oxidase, NG: normal glucose, HG: high glucose, HM: high mannitol, IL-1ȕ: interleukin-
1ȕ, NRVMs: neonatal rat ventricular myocytes. 
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7.2 Mitochondrial function in isolated cardiomyocytes exposed to HG and IL-1β 
Several studies have shown that hyperglycemia induces alterations in mitochondrial 
function in diabetic hearts [195-197]. It has been demonstrated that cardiac mitochondria 
from diabetic rats display decreased respiration and increased susceptibility to undergo 
calcium-mediated mitochondrial permeability transition [198-β00]. Emerging evidence 
suggests that hyperglycemia-induced oxidative stress could lead to mitochondrial dysfunction 
in the heart. Thus, we investigated whether also in HG- and IL-1ȕ-treated cardiomyocytes 
ROS formation was accompanied by mitochondrial dysfunction and whether MAO-generated 
ROS might contribute to mitochondrial damage in these conditions.  
To assess mitochondrial function, we measured ΔΨm by means of the fluorescent 
indicator TMRM. HG treatment in NRVMs did not show any changes in ΔΨm even after 48 
h (Figure 16A). These results prompted us to examine whether HG is inducing latent 
mitochondrial dysfunction. It is well established that ATP synthase can mask the loss of ΔΨm 
by working in a reverse mode [β01]. The respiratory chain generates a proton gradient across 
the IMM, with a higher concentration of H+ ions in the intermembrane space and a lower 
concentration in the matrix. ATP synthase uses this proton gradient to synthesize ATP from 
adenosine di-phosphate (ADP) and phosphate (Pi). Under stress conditions, when 
mitochondrial respiratory chain is dysfunctional and proton gradient is impaired, ATP 
synthase may start working in a reverse mode hydrolyzing glycolytically synthesized ATP in 
order to maintain the ΔΨm [β01]. Thus, to assess whether ATP synthase activity was 
compensating for the dysfunctional respiratory chain in HG-treated NRVMs, we monitored 
TMRM fluorescence intensity in presence of ATP synthase inhibitor oligomycin. NG- or 
HM-treated cells were able to maintain ΔΨm up to 1 hour following oligomycin 
administration (Figure 16B). On the other hand, TMRM fluorescence intensity started 
dropping immediately in HG-treated cells upon oligomycin addition. These results suggest 
that HG induced mitochondrial dysfunction in NRVMs, but in order to maintain ΔΨm these 
cells hydrolyze glycolytically synthesized ATP by reversing the activity of ATP synthase. 
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Figure 16. Mitochondrial membrane potential in NRVMs following treatment with HG and/or 
IL-1β. (A) Mitochondrial membrane potential determined by TMRM in NRVMs treated with NG, HG 
and HM after 48 h with (black) or without (white) pargyline. (B) Kinetics experiments were 
performed to follow changes in mitochondrial membrane potential upon addition of oligomycin and 
FCCP (indicated by arrows). NG: normal glucose, HG: high glucose, HM: high mannitol, NRVMs: 
neonatal rat ventricular myocytes, TMRM: tetramethylrhodamine, FCCP: carbonyl cyanide-4-
(trifluoromethoxy) phenylhydrazone. 
On the contrary, ΔΨm was remarkably reduced in adult cardiomyocytes already after 
5h of HG treatment and this effect was further exacerbated when HG was combined with IL-
1ȕ (Figure 17). Noteworthy, since accumulation of MTR in mitochondria is ΔΨm dependent, 
loss of ΔΨm in these conditions might explain the absence of an additional increase in ROS 
levels (measured with MTR) in adult cardiomyocytes after HG+IL1-ȕ treatment. Cells pre-
treated with pargyline were able to maintain ΔΨm in both neonatal and adult cardiomyocytes, 
indicating that MAO-generated ROS trigger mitochondrial dysfunction in cardiomyocytes 
treated with HG and/or IL-1ȕ. 
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Figure 17. Mitochondrial membrane potential in adult mouse cardiac myocytes following 
treatment with HG and/or IL-1β. Adult cardiomyocytes were treated with NG (5 mM), HG (β5 
mM) in presence or absence of IL-1ȕ (β5 ng/ml), with or without pargyline (100 µM) for 5 h. 
Mitochondrial membrane potential was measured with the fluorescent dye TMRM. *p<0.005 vs NG 
vehicle, #p<0.005 vs HG+IL-1ȕ vehicle. NG: normal glucose, HG: high glucose, IL-1ȕ: interleukin-
1ȕ, TMRM: tetramethylrhodamine, methyl ester. 
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7.3 MAO-generated ROS perturb ER function in cardiomyocytes exposed to 
HG and pro-inflammatory stimuli  
Accumulating evidence suggests that, in addition to oxidative stress and inflammation, 
ER stress also contributes to the development of diabetic cardiomyopathy [β4, 145, β0β]. 
Several pathological conditions can lead to the accumulation of misfolded proteins in the ER 
lumen leading to the activation of UPR. It was reported that hyperglycemia-induced ER stress 
is involved in myocardial apoptosis leading to cardiac dysfunction in diabetic rodents [β0γ]. 
Although many studies have linked ER and oxidative stress in pathological conditions, 
molecular pathways that couple these processes are poorly understood. Thus, to better 
understand the cross-communication between these two organelles we initially investigated 
whether, in addition to targeting mitochondria, HG and IL-1ȕ can also perturb ER function. 
Therefore, we measured gene and protein expression of several ER stress markers, such as 
ATF4, CHOP, XBP1, GADDγ4 and GRP78.  
Using NRVMs as a model, we were unable to detect prominent ER stress at different 
time points (γ h, 6 h, 1β h, β4 h and 48 h) following treatment with HG or the combination of 
HG and IL-1ȕ. IL-1ȕ alone led to a mild but significant increase in the expression of ATF4, 
CHOP and spliced XBP1 marking the occurrence of ER stress after 48h (Figure 18A). Unlike 
IL-1ȕ, HG did not show any significant changes in ER stress markers, whereas the 
combination of HG and IL-1ȕ led to an increase only in spliced XBP1 levels. Pargyline 
completely prevented this increase suggesting that MAO-generated ROS formation 
contributes to UPR activation (Figure 18B). 
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Figure 18. UPR in NRVMs exposed to HG and pro-inflammatory cytokine IL-1β. (A) Gene 
expression of ER stress markers involved in UPR was assessed in NRVMs treated in different 
conditions after 48h. (B) Effects of pargyline on IL-1ȕ-induced gene expression of ER stress markers 
in NRVMs. *§p<0.05 vs NG, #p<0.05 vs NG+IL-1ȕ. UPR: unfolded protein response, NG: normal 
glucose, HG: high glucose, NRVMs: neonatal rat ventricular myocytes, IL-1ȕ: interleukin-1ȕ, ER: 
endoplasmic reticulum. 
On the other hand, exposure of adult cardiomyocytes to HG resulted in stronger 
induction of ER stress. Expression levels of ER chaperone GRP78/BiP was ~γ fold 
upregulated in presence of HG and HG-IL1ȕ as shown in Figure 19. GRP78 is the central 
regulator of ER stress and it binds to the luminal domains of three ER transmembrane 
proteins, namely IRE1α, PERK and ATF6, thereby keeping them inactive. Upon ER stress, 
GRP78 dissociates from these sensor proteins resulting in their activation [1γ8]. Accordingly, 
phosphorylation levels of IRE1α, an ER transmembrane kinase, were also increased in these 
cells further confirming the activation of UPR. We also assessed the expression of other 
proteins downstream of GRP78, such as transcription factor ATF4 and growth arrest and 
DNA damage-inducible protein GADDγ4. Both ATF4 and GADDγ4 were also upregulated 
by HG and IL-1ȕ treatment as shown in Figure 19. Interestingly, MAO inhibition completely 
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prevented the activation of UPR induced by HG and IL-1ȕ in adult cardiomyocytes. These 
results indicate that MAO-dependent ROS formation not only targets mitochondria to induce 
mitochondrial dysfunction, but it can also perturb ER homeostasis leading to the activation of 
UPR. In addition, we show that mitochondrial ROS formation and dysfunction are upstream 
of ER stress, at least in these conditions. 
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Figure 19. ER stress in adult cardiomyocytes exposed to HG and/or IL-1β. Protein expression of 
ER stress markers, GRP78, GADDγ4, ATF4 and phosphorylation levels of IRE1α were assessed in 
adult cardiomyocytes after 48 h of treatment with HG and/or IL-1ȕ with or without pargyline (100 
µM). Protein expression was normalized to total protein determined by Red Ponceau staining. 
*p<0.005 vs NG vehicle, #p<0.005 vs HG-IL1ȕ vehicle. ER: endoplasmic reticulum, NG: normal 
glucose, HG: high glucose, IL-1ȕ: interleukin-1ȕ, GRP78: 78 kDa glucose-regulated protein, 
GADDγ4: growth arrest and DNA damage-inducible protein, ATF4: activating transcription factor, 
IRE1α: inositol-requiring enzyme 1α. 
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7.4 ER stress induced by tunicamycin and thapsigargin is MAO independent 
Considering that MAO-generated ROS formation appears to be upstream of ER stress 
when cells are treated with HG and pro-inflammatory stimuli, we next examined whether 
direct induction of ER stress in NRVMs with tunicamycin or thapsigargin can affect 
mitochondrial ROS formation and function in a MAO-dependent manner. Tunicamycin 
inhibits the synthesis of glycoproteins in the lumen of ER leading to the accumulation of 
unfolded proteins and UPR activation [1γγ]. Thapsigargin instead causes a reduction in ER 
calcium levels due to the inhibition of SERCA. This results in the loss of activity of calcium-
dependent ER chaperones, such as calnexin, and accumulation of unfolded proteins. Initially, 
a dose dependent curve was performed to find the optimal concentration of tunicamycin and 
thapsigargin required to induce ER stress. We found that 1 μg/ml tunicamycin and 1 μM 
thapsigargin induced maximum ER stress after overnight incubation. Gene expression of 
transcription factor ATF4 and pre-apoptotic gene CHOP was 4 fold upregulated in these 
conditions, indicating the activation of PERK/eIFβα/ATF4 pathway (Figure β0 A). 
Furthermore, the ratio of spliced/unspliced XBP1 was ~4 fold higher in the cells treated with 
tunicamycin and thapsigargin. All of the UPR markers were significantly reduced by the 
chemical chaperone TUDCA (Figure β0B). We also observed that ER stress was 
accompanied by ROS formation in these conditions. Tunicamycin and thapsigargin both led 
to a significant increase in ROS formation measured with MTR (Figure β0C, D). As 
expected, this severe ER stress also led to a 40% decrease in cell viability (Figure β0E, F). To 
investigate whether MAO plays any role in ER stress-induced cell damage cells were co-
treated with MAO inhibitor pargyline in these conditions. We found that MAO inhibition did 
not have any effect on thapsigargin induced cell damage. However, tunicamycin induced 
ROS formation was partially reduced upon pargyline treatment (Figure β0C) with no effects 
observed on ER stress markers and cell death (Figure β0B, E).  
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Figure 20. Tunicamycin and thapsigargin induced cell damage in NRVMs. (A) Gene expression 
of ER stress markers, ATF4, CHOP and sXBP1/tXBP1. (B) Effects of pargyline and TUDCA on 
tunicamycin-induced ER stress markers. (C-D) Cell viability and (E-F) ROS formation induced by 
tunicamycin (1 µg/ml) and thapsigargin (1 µM) in NRVMs with and without pargyline (100 µM). 
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Chemical chaperone TUDCA was used as a positive control. *p<0.005 vs control vehicle. NRVMs; 
neonatal rat ventricular myocytes, ER: endoplasmic reticulum, ATF4: activating transcription factor, 
CHOP: CCAAT-enhancer-binding protein homologous protein, s/tXBP1: spliced/total X-box binding 
protein 1, TUDCA: tauroursodeoxycholic acid, ROS: reactive oxygen species. 
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7.5 MAO contributes to LV diastolic dysfunction in STZ-induced T1D mice 
Cardiovascular complications are one of the most common causes of death among 
diabetic patients. Several studies have characterized a number of functional changes that 
develop early in the course of diabetic cardiomyopathy. To investigate whether MAO 
contributes to oxidative stress and cardiac dysfunction occurring in diabetes, we used STZ-
induced T1D mice. C57BL6/J male mice were anesthetized and injected intraperitoneally 
(i.p) with STZ (50 mg/kg) for 5 consecutive days to induce T1D. STZ causes pancreatic ȕ-
cell necrosis and thus inhibits glucose-induced insulin secretion leading to the development of 
T1D [β04]. After 1β weeks of STZ treatment, we assessed LV function in these mice via PV 
relationships, as shown in Figure β1A.  
 
Figure 21. Characterization of LV function in STZ-induced T1D mice. (A) Representative 
pressure-volume loops from control (blue), STZ (black), control+pargyline (green) and 
STZ+pargyline (red) treated mice. (B) Ejection fraction and (C) Diastolic stiffness measurement in 
vehicle or pargyline treated control and STZ mice. *p<0.005 vs CT vehicle, †p<0.005 vs STZ vehicle. 
LV: left ventricle, STZ: streptozotocin, T1D: type 1 diabetes. 
Heart rate and cardiac output remained unchanged between the experimental groups 
(Table 1). Moreover, we found that ejection fraction, an index of systolic function, was also 
unaffected in STZ-mice (Figure β1B). dP/dtmax and dP/dtmin, indexes of contractility and 
relaxation, showed a trend to decrease in STZ-treated mice but these changes were not 
statistically significant (Table 1). This suggests that, although systolic function still appears 
unaffected, STZ mice are likely to undergo systolic dysfunction with prolonged treatment. 
Interestingly, diastolic stiffness, an index of diastolic dysfunction, was 4.6-fold increased in 
diabetic mice (Figure β1C). These findings are consistent with clinical reports showing that 
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LV diastolic dysfunction is one of the earliest signs of cardiac complications in diabetic 
patients, followed by systolic dysfunction only at later stages [β7, β05]. To assess whether 
MAO activity might play a role in the development of diabetic cardiomyopathy, cardiac 
function was evaluated also in STZ-mice that were administered MAO inhibitor pargyline. 
Importantly, MAO inhibition did not affect any of the LV functional parameters in the control 
group, as indicated in Table 1. However, pargyline administration significantly reduced 
diastolic stiffness in STZ-mice, indicating a pivotal role of these flavoenzymes in LV 
dysfunction in diabetic cardiomyopathy. 
 Control (n=6) Control+Parg (n=4) STZ (n=8) 
STZ+Parg 
(n=10) 
Glucose (mmol/l) 10.β0±1.40 8.60±0.40 γβ.β0±γ0* γβ.10±γ.10* 
Body weight (g) γγ.10±β.70 γβ.40±β.00 β5.50±4.γ0 β4.β0±5.γ0 
Heart rate (bpm) γ80.56±β0.4β 446.59±β1.90 γ50.57±16.58 γ4γ.8γ±1.94 
EDV (µl) 65.66±9.4γ 70.50±β.60 47.6β±γ.5β* 50.70±β.87* 
ESV (µl) β1.50±4.β8 β7.00±1.41 14.87±1.74 15.γ0±1.49 
SV (µl) 44.16±5.γ1 4γ.50±β.γ8 γβ.87±β.1β* γ5.β0±β.11* 
EF (%) 68.01±β.06 61.75±β.07 69.γ4±1.76 69.8β±1.88 
Diast stiff (1/µl) 0.0158±0.005 0.010±0.004 0.069±0.009* 0.0γγ1±0.007† 
ESP (mmHg) 8β.66±β.γ9 91.6γ±5.7β 67.47±5.67 76.β0±1.94 
EDP (mmHg) 8.58±1.5γ 5.98±1.79 9.β1±β.β0 10.γβ±1.75 
dP/dtmax (mmHg/s) 5487.40±4γ0.94 71β0.β9±5ββ.16 4101.85±645.78 471γ.β8±γ16.7 
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dP/dtmin (mmHg/s) -59γ0.80±γ89.β -7161.70±804.γ6 -4001.γ0±886.90 -4500.β9±885.7 
Eff (%) 7γ.γ5±4.15 70.γ7±17.0β 76.ββ±6.6β 74.06±5.γ6 
Table 1. Glycemic and hemodynamic parameters measured in T1D mice. EDV: end-diastolic 
volume, ESV: end-systolic volume, SV: stoke volume, EF: ejection fraction, CO: cardiac output, ESP: 
end-systolic pressure, EDP: end diastolic pressure, Eff: efficiency. *p<0.005 vs Control, †p<0.005 vs 
STZ. T1D: type 1 diabetes. 
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7.6 MAO contributes to oxidative stress and impairs ER homeostasis in diabetic 
hearts 
Accumulating evidence supports the role of oxidative stress and ER stress in diastolic 
dysfunction occurring in both diabetic patients and animal models. Thus, we investigated 
whether oxidative stress and impaired ER function might contribute to LV diastolic 
dysfunction also in our T1D model. To measure oxidative stress in T1D hearts we assessed 
the levels of 4-HNE, a product of lipid peroxidation. 4-HNE is a highly reactive aldehyde that 
modifies proteins, phospholipids and nucleic acids. Thus, it is widely used as an oxidative 
stress marker. As expected, we found that levels of 4-HNE were significantly increased in 
T1D hearts indicating the occurrence of oxidative stress in these mice (Figure ββ).  
 
Figure 22. Oxidative stress in STZ-induced T1D mice. 4-HNE staining was performed on heart 
tissue lysates extracted from vehicle- or pargyline-treated control and STZ mice. 4-HNE levels were 
normalized to total protein content determined by Red Ponceau. *p<0.05 vs control, #p<0.05 vs STZ. 
STZ: streptozotocin, T1D: type 1 diabetes, 4-HNE: 4-hydroxy-β-nonenal. 
Moreover, oxidative stress was accompanied by impaired ER homeostasis in STZ-mice 
as demonstrated by induction of UPR associated proteins, including ATF4 and GADDγ4 
(Figure βγ). In line with our in vitro data, pargyline administration to diabetic mice 
completely prevented these alterations. These results suggest that hyperglycemia-induced 
changes in diabetic hearts lead to the enhanced MAO activity resulting in oxidative stress. As 
a consequence, misfolded proteins accumulate in the ER leading to the activation of UPR. 
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This data further support previous studies suggesting that oxidative and ER stress contribute 
to the pathogenesis of diabetic cardiomyopathy [9γ, β06]. 
 
Figure 23. ER stress in STZ-induced T1D mice. (A) Representative western blot and (B) 
quantification of ATF4 and GADDγ4 band intensities in heart tissue lysates of control, STZ and 
STZ+pargyline treated mice. *p<0.05 vs control, #p<0.05 vs STZ. ER: endoplasmic reticulum, T1D: 
type 1 diabetes, STZ: streptozotocin, ATF4: activating transcription factor 4, GADDγ4: growth arrest 
and DNA damage-inducible protein. 
We also investigated whether the increase in oxidative stress was due to changes in 
MAO protein expression in diabetic conditions. In agreement with our in vitro data, the 
protein expression of MAO-B, predominant isoform in the mouse heart, was not significantly 
different in STZ hearts as compared to controls (Figure β4).  
 
Figure 24. MAO-B protein expression in heart tissue lysates. MAO-B protein expression in heart 
tissue lysates of control, STZ and STZ+pargyline treated mice. MAO: monoamine oxidase, STZ: 
streptozotocin. 
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7.7 MAO activity triggers mast cell degranulation and cardiac fibrosis in T1D 
mice in vivo 
Cardiac fibrosis is one of the underlying causes of diastolic dysfunction and a major 
feature of diabetic cardiomyopathy [β4, γ7]. Collagen synthesis is enhanced, whereas its 
degradation is limited in pathological conditions, creating a net excess of collagen deposition 
[β07]. An over-production of collagen is known to increase myocardial stiffness and 
consequent cardiac dysfunction, ultimately resulting in cardiac failure [γ7, β08]. Hence, we 
assessed collagen levels in our diabetic model using Masson’s Trichrome staining. Indeed, we 
found a 4-fold increase in collagen deposition in STZ-hearts as shown in Figure β5. 
Surprisingly, pargyline treated mice showed complete absence of these histological 
alterations suggesting that MAO plays a crucial role in the development of fibrosis in these 
animals.  
 
Figure 25. Cardiac fibrosis in T1D mice. (A) Representative images of Masson’s trichrome staining 
from control and STZ mice, showing collagen deposition in blue. (B) The quantification data is 
expressed as percentage of fibrotic vs total cardiac tissue. *p<0.05 vs control vehicle, #p<0.05 vs 
control vehicle. T1D: type 1 diabetes, STZ: streptozotocin. 
One of the mechanisms leading to the development of fibrosis is mast cell 
degranulation [β09]. Mast cells are known to play a key role in the inflammatory processes 
and, when stimulated, can undergo degranulation to release a number of pro-inflammatory 
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and pro-fibrotic factors [β10]. Several studies linked increased ROS production and mast cell 
degranulation in pathological conditions [16γ-165]. Indeed, multiple studies have 
demonstrated that incubation of mast cells with HβOβ lead to a dose-dependent increase in 
mast cell degranulation in vitro [165]. Moreover, Luo et al. and Gan et al. have shown that 
specific inhibition of ROS-generating enzyme  
oxidase by apocynin in a model of intestinal ischemia-reperfusion-induced acute lung injury 
completely abolished the activation of mast cells [164, 165]. However, whether mitochondria 
and ROS are involved in triggering cardiac mast cell degranulation in diabetic 
cardiomyopathy is not yet clear. Thus, to understand whether mast cell degranulation is 
triggering fibrosis and if MAO activity is involved in this inflammatory process, we assessed 
cardiac mast cell density and level of degranulation in STZ mice. No significant difference 
was observed in the density of mast cell between STZ hearts and control mice (Figure β6B). 
However, mast cell degranulation was 1.8-fold higher in diabetic mice as compared to control 
(Figure β6C). Interestingly, pargyline treatment prevented mast cell degranulation in T1D 
mice. Taken together, these results suggest that MAO is involved in the activation of cardiac 
mast cells thereby leading to the remodeling of the extracellular matrix, fibrosis and, 
ultimately, LV dysfunction. These findings complement previous studies reporting that 
myocardial remodeling is associated with cardiac mast cell activation in diabetic 
cardiomyopathy [β11]. However, further investigation is required to elucidate how the 
activity of these flavoenzymes triggers mast cell degranulation.  
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Figure 26. Mast cell degranulation in STZ-induced T1D mice. (A) Representative images of 
toluidine blue staining of cardiac tissue from indicated experimental groups. Red arrows indicate 
intact mast cells, while black arrows indicate actively degranulating mast cells. Quantification of (B) 
mast cell density and (C) mast cell degranulation. Results are expressed as number of mast cells per 
field and percentage of degranulating mast cells vs total number of mast cells, respectively.*p<0.05 vs 
control vehicle, #p<0.05 vs STZ vehicle. STZ: streptozotocin, T1D: type 1 diabetes. 
  
86 
 
8. DISCUSSION AND CONCLUSIONS 
This study demonstrates that MAOs play a prominent role in HG and/or IL-1ȕ induced 
mitochondrial ROS formation and dysfunction in vitro, and cardiac damage in T1D mice in 
vivo. We also show that ROS produced by these flavoenzymes can also perturb ER function 
leading to the activation of UPR in diabetic conditions. Furthermore, we describe the novel 
role of MAO in the activation of cardiac mast cells thereby providing an important link 
between MAO activity, inflammation and fibrosis in diabetic cardiomyopathy.  
Several hypotheses for the mechanism underlying hyperglycemia-induced cardiac 
impairment include an increase in polyol pathway flux, intracellular AGE formation or 
increased flux through the hexosamine pathway [β1β, β1γ]. Many alterations of cellular and 
mitochondrial metabolism observed during the development of diabetic cardiomyopathy are 
associated with increased ROS levels. Multiple studies indicated that cardiac impairment is 
not caused by hyperglycemia per se, but rather it is the oxidative stress and inflammation that 
lead to cardiovascular complications. Moreover, clinical studies validated IL-1ȕ, a pro-
inflammatory cytokine, as a target to improve glucose metabolism and cardiac complications 
in patients with both T1D and TβD [β14-β16]. It is well known that mitochondrial ROS 
formation and dysfunction lead to the production of IL-1ȕ via inflammasome pathway [186, 
β17], but whether and how IL-1ȕ can induce mitochondrial ROS formation has never been 
investigated. Here, we show for the first time that IL-1ȕ, in combination with HG, is able to 
induce mitochondrial ROS formation and, importantly, this occurs in a MAO-dependent 
manner. We demonstrate that MAO-induced ROS formation is remarkably increased when 
cells are treated with the combination of HG and IL-1ȕ, as compared to either of them alone. 
The exacerbated ROS formation in these conditions is more evident in NRVMs as compared 
to adult cardiomyocytes. The reason behind this discrepancy is likely due to technical 
limitations of the MTR probe, as mentioned in the Results section. Overall, our in vitro 
results indicate that adult cardiomyocytes are more susceptible to HG and pro-inflammatory 
stimuli as compared to NRVMs. This is supported by the observation that HG led to a mild 
increase in ROS formation in NRVMs after 48 h, whereas adult cardiomyocytes displayed a 
β-fold increase in ROS formation within β hours of treatment. Moreover, NRVMs did not 
display any change in ΔΨm even after 48 h of treatment with HG, while adult 
cardiomyocytes show a β-fold and 9-fold reduction in ΔΨm in presence of HG and HG-IL1ȕ, 
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respectively. Finally, we also observed that NRVMs do not show remarkable changes in the 
expression of ER stress markers, whereas adult cardiomyocytes underwent strong impairment 
of ER homeostasis and upregulation of UPR markers. This discrepancy might be due to the 
glycolytic phenotype of neonatal cardiomyocytes or due to the differences in the antioxidant 
defense system between these two cultures [19γ, β18]. Thus, it is important to take these 
notions into consideration when choosing the adequate model for the assessment of the 
effects following exposure to the diabetic milieu.  
MAO-generated HβOβ is not only confined to mitochondria, but also occurs in the 
cytosol in HG- and/or IL-1ȕ- treated cardiomyocytes. In recent years, it has been shown that 
mitochondrial impairment can induce cytosolic ROS formation and vice-versa. Maharjan et 
al. demonstrated that proteasome inhibition causes an increase in mitochondrial ROS 
formation and dysfunction leading to cytosolic oxidative stress [β19]. On the other hand, 
Coughlan et al. reported that exposure of primary renal cells to AGEs leads to an increase in 
cytosolic ROS formation which facilitated the production of mitochondrial superoxide and 
deficiency of mitochondrial complex I [ββ0]. Thus, it remains an open question whether in 
our experimental model mitochondrial ROS occurs prior to cytosolic oxidative stress. 
However, previous data obtained in our laboratory suggest that in cardiomyocytes MAO-
induced ROS formation occurs firstly in mitochondria and then in the cytosol [1β0].  
It is important to understand why and how the activity of MAO is upregulated in 
diabetic conditions. Although MAO protein expression remains unchanged both in vitro and 
in vivo, increased substrate availability and/or post-translational modifications might account 
for the enhanced activity of these enzymes. Indeed, our laboratory has previously 
demonstrated that enhanced MAO-A-dependent norepinephrine degradation contributes to 
oxidative stress and transition from compensated hypertrophy to heart failure in pressure 
overloaded mice [117]. However, catecholamines are mainly stored in the sympathetic nerve 
endings and, at present, it still remains to be elucidated whether these or other MAO 
substrates may also be stored in cardiac myocytes.  
We also demonstrated that MAO is involved in HG and pro-inflammatory stimuli 
induced mitochondrial dysfunction. It has been previously shown in a model of Parkinson’s 
disease that increased MAO activity can affect mitochondrial function by decreasing 
mitochondrial complex I activity, thus impairing electron transport chain [ββ1]. Our data 
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demonstrate that MAO-generated HβOβ leads to reduced ΔΨm, most likely due to the 
impairment of the mitochondrial respiratory chain. Besides HβOβ formation, these 
flavoenzymes also produce aldehydes and ammonia [110, 115, 1βγ]. Recent studies have 
focused on the deleterious effects of reactive aldehydes in cardiac diseases. It has been 
demonstrated that aldehydes can perturb mitochondrial function by directly targeting 
pyruvate dehydrogenase and complex I-associated proteins [βββ]. Moreover, Zhang et al. 
showed that mitochondrial ALDHβ, improves mitochondrial function and reduces apoptosis 
in STZ-induced T1D hearts [ββγ]. Thus, it might be possible that MAO-induced 
mitochondrial dysfunction in cardiomyocytes is a combined effect of increased ROS levels 
and aldehydes upon HG and IL-1ȕ exposure.  
Our data demonstrate that in addition to oxidative stress and mitochondrial dysfunction, 
MAO activity also leads to the impairment of ER homeostasis and activation of UPR in both 
in vitro and in vivo model of diabetes, highlighting the novel role of these flavoenzymes in 
the interplay between ER and mitochondria. Persistent protein misfolding is known to play 
predominant roles in the pathogenesis of multiple cardiovascular diseases including diabetes, 
heart failure, and ischemia/reperfusion injury [144, ββ4, ββ5]. Although many studies have 
shown an association between oxidative and ER stress, whether mitochondrial ROS 
formation is upstream of ER stress or vice-versa is not clear. It has been demonstrated that 
activation of UPR under stress conditions led to impaired calcium and redox homeostasis. As 
a consequence, oxidative stress is increased leading to impaired mitochondrial function [ββ6, 
ββ7]. Although the exact mechanism of how protein misfolding can trigger ROS formation is 
not yet fully understood, several possible mechanisms have been proposed. First, under stress 
conditions misfolded proteins bind to ER chaperone GRP78; this process requires ATP that 
may stimulate mitochondria to generate more ATP through oxidative phosphorylation leading 
to the production of ROS as a byproduct [ββ7]. Second, ROS may be produced as a 
consequence of disulfide bond formation. ER oxidoreductase proteins oxidize cysteine 
residues of nascent proteins, helping them in the formation and isomerization of correct 
disulfide bonds. Reduced folding enzymes are re-oxidized by ERO-1, the enzyme which 
reduces molecular oxygen leading to the production of HβOβ [ββ8]. On the other hand, 
Malhotra et al. suggested that both ROS and unfolded proteins are required to activate UPR in 
the cell. They further demonstrated that reducing ROS by the antioxidant butylated 
hydroxyanisole improves protein folding and cell survival [ββ9]. Furthermore, two 
independent studies reported that inhibition of oxidative stress by MitoTEMPO and ER stress 
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by TUDCA prevented diabetes-induced cardiac damage in rodents [145, βγ0]. These findings 
suggest the crucial need for understanding the pathological mechanisms that alter both 
organelles in pathological conditions, and particularly the mechanisms that coordinate the 
interplay between mitochondrial dysfunction and ER stress. In the present study we show that 
HG- and inflammation-induced ROS formation and mitochondrial dysfunction are upstream 
of ER stress in cardiomyocytes. Importantly, MAO contributes to perturbed ER function in 
HG/IL1ȕ-treated NRVMs in vitro and in T1D mice in vivo. These findings indicate the novel 
role of these flavoenzymes in the vicious cycle between excessive ROS formation and ER 
stress. However, MAO inhibition is not sufficient to protect the cell from damage when ER 
stress is induced directly and occurs upstream of mitochondrial ROS formation (Figure β0). 
This might be due to the fact that both tunicamycin and thapsigargin led to severe ER stress 
as demonstrated by the β0-fold increase in gene expression of ATF4 and pre-apoptotic gene 
CHOP. This increase is much higher compared to our in vitro diabetic model where we 
observed a γ-fold upregulation of ER stress markers (Figure 19). On the other hand, it is 
possible that tunicamycin- and thapsigargin-induced ER stress cause mitochondrial 
dysfunction, oxidative stress and cell death in a MAO-independent manner. Indeed, it has 
been shown that ER stress can cause mitochondria to produce more ROS causing cell death 
via induction of mitochondrial permeability transition, induced upon entry of excessive 
amounts of Caβ+ into the mitochondrial matrix [1γγ]. 
Besides the functional link between mitochondria and ER, the sites of physical 
communication between these organelles, known as mitochondria associated membranes 
(MAMs), have recently earned considerable attention. Indeed, some studies proposed that 
MAMs are involved in the maintenance of lipid and calcium homeostasis, in the initiation of 
autophagy and mitochondrial division, and in sensing metabolic shifts inside the cell [βγ1-
βγ5]. One study has highlighted the role of MAMs in diabetes demonstrating that obesity 
drives an abnormal increase in MAMs formation in the liver, resulting in increased Caβ+ flux 
from the ER to mitochondria [βγ6]. Downregulation of PACS-β, a protein important for ER-
mitochondria tethering, prevented these changes [βγ6]. Moreover, it has been shown that ER 
stress led to a remarkable increase in MAMs both in vitro and in the liver of obese mice in 
vivo [βγβ, βγ6]. Mitofusin β, a molecular tether between ER and mitochondria, has been 
shown to play a role in ER-mitochondria calcium cross-talk in cardiomyocytes and to be one 
of the factors that regulate events orchestrated by mitochondrial calcium uptake, such as 
metabolism, opening of the mitochondrial permeability transition pore (MPTP), and 
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programmed cardiomyocyte death [βγ7]. In addition to that, recent studies have shown that 
ER-mitochondria tethering enables ER proteins to associate directly with proteins and lipids 
of the OMM. It is therefore tempting to hypothesize that MAO, localized at the OMM, might 
interact with some of the ER proteins and also play a role in ER-mitochondria tethering. A 
coherent understanding of the bidirectional communication existing between these two 
organelles will certainly aid in the development of specific therapeutic strategies to treat 
diseases associated with oxidative stress, UPR and inflammation such as obesity, diabetic 
cardiomyopathy and neurological disorders. 
Oxidative stress and mitochondrial dysfunction are widely accepted to play an 
important role in the development and progression of LV dysfunction in diabetic 
cardiomyopathy [γ7, γ9, βγ8]. Recent studies documented mitochondrial dysfunction in 
human diabetic hearts showing an increased mitochondrial oxidative stress and increased 
sensitivity to calcium-induced opening of the MPTP in atrial tissue of patients [γ7, 85]. Here 
we provide strong evidence that diastolic dysfunction occurring in STZ mice is completely 
prevented upon MAO inhibition. These findings are of major importance because of their 
clinical relevance. Diastolic dysfunction detected at the initial stages of diabetes falls into the 
category of HFpEF, a condition that occurs in approximately 50% of patients with heart 
failure. The mechanisms of this modality are poorly understood because of the limited 
availability of animal models with HFpEF. Although the role of MAO in TAC-induced heart 
failure has already been reported [117], current data strongly suggests that targeting MAO 
activity might be particularly interesting in diabetic patients with HFpEF. 
Mitochondrial ROS formation is believed to be the primary cause for LV diastolic 
dysfunction [198, βγ8]. In this regard, Dai et al have shown that specific inhibition of 
mitochondrial ROS formation by synthetic Szeto-Schiller peptide SS-γ1prevented LV 
diastolic dysfunction, whereas non-targeted ROS scavenging with N-acetyl cysteine (NAC) 
had no effect [βγ9]. A recent study emphasized that already in prediabetic conditions ROS 
levels are elevated in subsarcolemmal mitochondria, further indicating that mitochondrial 
ROS production is one the earliest events to trigger cardiac pathological changes well before 
major metabolic derangements occur [β40]. Within this scenario, we provide strong evidence 
that specific inhibition of MAO activity in T1D results in improved cardiac function. 
Nevertheless, it remains to be elucidated whether MAO inhibition affords protection also 
when inhibitors are administered after the onset of diastolic dysfunction.  
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It appears that increased diastolic stiffness in STZ mice is the result of MAO-induced 
cardiac fibrosis, one of the major features of diabetic cardiomyopathy. Several factors have 
been reported to contribute to cardiac fibrosis, including cytokines, growth factors, infiltration 
of inflammatory cells monocyte/macrophages and degranulation of mast cells. In our T1D 
model, we found that MAO activity triggers mast cell degranulation that might be 
contributing to cardiac fibrosis and thus diastolic dysfunction. Although several studies hint 
to the link between mast cell and oxidative stress in different pathological disorders [161, 
16γ, 164, β09, β41], up to date no study has identified the specific source of ROS responsible 
for mast cell degranulation in diabetic cardiomyopathy. Here, we report for the first time that 
MAO activity triggers mast cell degranulation in STZ-mice, thus providing a mechanistic link 
between these mitochondrial flavoenzymes, inflammation and fibrosis in diabetic 
cardiomyopathy. Nevertheless, it still remains to be elucidated whether it is MAO-generated 
ROS formation in cardiomyocytes or in mast cells themselves that is triggering this 
inflammatory response.  
Since oxidative stress is known to play a major role in the development of 
cardiovascular complications in diabetes, several therapies aimed at reducing ROS formation 
and enhancing antioxidant defense have been employed to improve cardiac dysfunction in 
rodents. In contrast, large-scale clinical trials using antioxidant therapies for the treatment of 
these pathological disorders have been ineffective [β4β, β4γ]. Collectively, these studies point 
towards a serious need to develop therapeutic strategies aimed at inhibiting specific sources 
of ROS in pathological conditions. We demonstrate that MAO contributes to increased ROS 
formation and ER stress in HG and IL-1ȕ treated cardiomyocytes in vitro and in T1D model 
in vivo. Moreover, we show that these enzymes further activate cardiac mast cells, leading to 
fibrosis and ultimately diastolic dysfunction. These results point to MAO inhibition as a 
potential therapy in diabetic cardiomyopathy. Moreover, as mentioned before, besides the 
generation of HβOβ these flavoenzymes also produce reactive aldehydes that, per se, are 
deleterious for the heart. Thus, therapy employing MAO inhibition in cardiac dysfunction 
will not only aim at reducing oxidative stress but also abolishing the detrimental effects of 
these reactive aldehydes.  
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